DE19857492A1 - Cosmetic or dermatological skin-protective compositions, containing saturated phosphatidyl choline to give good barrier stabilizing and active agent penetrating effects - Google Patents
Cosmetic or dermatological skin-protective compositions, containing saturated phosphatidyl choline to give good barrier stabilizing and active agent penetrating effectsInfo
- Publication number
- DE19857492A1 DE19857492A1 DE1998157492 DE19857492A DE19857492A1 DE 19857492 A1 DE19857492 A1 DE 19857492A1 DE 1998157492 DE1998157492 DE 1998157492 DE 19857492 A DE19857492 A DE 19857492A DE 19857492 A1 DE19857492 A1 DE 19857492A1
- Authority
- DE
- Germany
- Prior art keywords
- weight
- skin
- substances
- phosphatidylcholine
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 239000002537 cosmetic Substances 0.000 title claims abstract description 24
- 150000008105 phosphatidylcholines Chemical class 0.000 title claims abstract description 10
- 230000004888 barrier function Effects 0.000 title claims description 14
- 230000000087 stabilizing effect Effects 0.000 title claims description 4
- 239000013543 active substance Substances 0.000 title abstract description 8
- 230000000149 penetrating effect Effects 0.000 title description 2
- 239000003381 stabilizer Substances 0.000 title description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 47
- 229940057917 medium chain triglycerides Drugs 0.000 claims abstract description 41
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 238000009472 formulation Methods 0.000 claims abstract description 8
- 239000000126 substance Substances 0.000 claims description 55
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 54
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 35
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 33
- 229920006395 saturated elastomer Polymers 0.000 claims description 33
- 239000004480 active ingredient Substances 0.000 claims description 31
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 24
- 229940043375 1,5-pentanediol Drugs 0.000 claims description 20
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 20
- 239000004202 carbamide Substances 0.000 claims description 17
- 235000011187 glycerol Nutrition 0.000 claims description 17
- -1 antifungals Substances 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 12
- 230000003020 moisturizing effect Effects 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 150000004665 fatty acids Chemical class 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 230000037380 skin damage Effects 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 6
- 239000001993 wax Substances 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 229910001385 heavy metal Inorganic materials 0.000 claims description 5
- 239000000049 pigment Substances 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- 239000003906 humectant Substances 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 239000008158 vegetable oil Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 208000003251 Pruritus Diseases 0.000 claims description 3
- 230000002421 anti-septic effect Effects 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 229940064004 antiseptic throat preparations Drugs 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 229940121357 antivirals Drugs 0.000 claims description 3
- 239000003212 astringent agent Substances 0.000 claims description 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 3
- 239000012138 yeast extract Substances 0.000 claims description 3
- 229940035674 anesthetics Drugs 0.000 claims description 2
- 230000002924 anti-infective effect Effects 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 229960005475 antiinfective agent Drugs 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 claims description 2
- 239000003193 general anesthetic agent Substances 0.000 claims description 2
- 239000000419 plant extract Substances 0.000 claims description 2
- 150000003841 chloride salts Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 230000006378 damage Effects 0.000 abstract description 6
- 210000003491 skin Anatomy 0.000 description 143
- 238000002360 preparation method Methods 0.000 description 73
- 239000005995 Aluminium silicate Substances 0.000 description 33
- 235000012211 aluminium silicate Nutrition 0.000 description 33
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 33
- 235000002639 sodium chloride Nutrition 0.000 description 30
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 239000000047 product Substances 0.000 description 20
- 239000011780 sodium chloride Substances 0.000 description 15
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 201000004681 Psoriasis Diseases 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 10
- 206010000496 acne Diseases 0.000 description 9
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 9
- 229920001285 xanthan gum Polymers 0.000 description 9
- 208000002874 Acne Vulgaris Diseases 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- ULQISTXYYBZJSJ-UHFFFAOYSA-N R-12-HOA Natural products CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 6
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 6
- 230000035515 penetration Effects 0.000 description 6
- 229920000058 polyacrylate Polymers 0.000 description 6
- 208000017520 skin disease Diseases 0.000 description 6
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 5
- 241001135917 Vitellaria paradoxa Species 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 235000021302 avocado oil Nutrition 0.000 description 5
- 239000008163 avocado oil Substances 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 235000008524 evening primrose extract Nutrition 0.000 description 5
- 239000010475 evening primrose oil Substances 0.000 description 5
- 229940089020 evening primrose oil Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 5
- 229960004889 salicylic acid Drugs 0.000 description 5
- 229940057910 shea butter Drugs 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- YNQGVRJFSHTULP-UHFFFAOYSA-N 11-hydroxyhexadecanoic acid Chemical compound CCCCCC(O)CCCCCCCCCC(O)=O YNQGVRJFSHTULP-UHFFFAOYSA-N 0.000 description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 4
- 241000208680 Hamamelis mollis Species 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 201000009053 Neurodermatitis Diseases 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229940107161 cholesterol Drugs 0.000 description 4
- 239000003344 environmental pollutant Substances 0.000 description 4
- 239000008350 hydrogenated phosphatidyl choline Substances 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 231100000719 pollutant Toxicity 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 229940118846 witch hazel Drugs 0.000 description 4
- 235000010493 xanthan gum Nutrition 0.000 description 4
- 239000000230 xanthan gum Substances 0.000 description 4
- 229940082509 xanthan gum Drugs 0.000 description 4
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 3
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 3
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940106189 ceramide Drugs 0.000 description 3
- 150000001783 ceramides Chemical class 0.000 description 3
- 229940110456 cocoa butter Drugs 0.000 description 3
- 235000019868 cocoa butter Nutrition 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- 229940119170 jojoba wax Drugs 0.000 description 3
- 229960004194 lidocaine Drugs 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 229940101267 panthenol Drugs 0.000 description 3
- 239000011619 pantothenol Substances 0.000 description 3
- 235000020957 pantothenol Nutrition 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 3
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 230000037307 sensitive skin Effects 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 2
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 2
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 2
- 240000000912 Macadamia tetraphylla Species 0.000 description 2
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 240000008916 Oenothera biennis Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 235000001537 Ribes X gardonianum Nutrition 0.000 description 2
- 235000001535 Ribes X utile Nutrition 0.000 description 2
- 235000016919 Ribes petraeum Nutrition 0.000 description 2
- 244000281247 Ribes rubrum Species 0.000 description 2
- 235000002355 Ribes spicatum Nutrition 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 235000014104 aloe vera supplement Nutrition 0.000 description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960002255 azelaic acid Drugs 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229940074979 cetyl palmitate Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 239000005068 cooling lubricant Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229940000033 dermatological agent Drugs 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940043259 farnesol Drugs 0.000 description 2
- 229930002886 farnesol Natural products 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 229960004716 idoxuridine Drugs 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000010466 nut oil Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000011814 protection agent Substances 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 229960003656 ricinoleic acid Drugs 0.000 description 2
- 239000010667 rosehip oil Substances 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000008348 synthetic phosphatidyl choline Substances 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- 239000010497 wheat germ oil Substances 0.000 description 2
- 239000008207 working material Substances 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 1
- XLYMOEINVGRTEX-ONEGZZNKSA-N (e)-4-ethoxy-4-oxobut-2-enoic acid Chemical compound CCOC(=O)\C=C\C(O)=O XLYMOEINVGRTEX-ONEGZZNKSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- RNKMOGIPOMVCHO-SJMVAQJGSA-N 1,3,6-trigalloyl glucose Chemical compound C([C@@H]1[C@H]([C@@H]([C@@H](O)[C@H](OC(=O)C=2C=C(O)C(O)=C(O)C=2)O1)OC(=O)C=1C=C(O)C(O)=C(O)C=1)O)OC(=O)C1=CC(O)=C(O)C(O)=C1 RNKMOGIPOMVCHO-SJMVAQJGSA-N 0.000 description 1
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- XNMYNYSCEJBRPZ-UHFFFAOYSA-N 2-[(3-butyl-1-isoquinolinyl)oxy]-N,N-dimethylethanamine Chemical compound C1=CC=C2C(OCCN(C)C)=NC(CCCC)=CC2=C1 XNMYNYSCEJBRPZ-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 description 1
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 150000004325 8-hydroxyquinolines Chemical class 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241000049213 Aloe gariepensis Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000372033 Andromeda Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229910052582 BN Inorganic materials 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- PZNSFCLAULLKQX-UHFFFAOYSA-N Boron nitride Chemical compound N#B PZNSFCLAULLKQX-UHFFFAOYSA-N 0.000 description 1
- JNFJFHICLDHMID-UHFFFAOYSA-N C(CCCCCCC)C(C(=O)O)CCCCCCCCCC(CCCCCC)O Chemical compound C(CCCCCCC)C(C(=O)O)CCCCCCCCCC(CCCCCC)O JNFJFHICLDHMID-UHFFFAOYSA-N 0.000 description 1
- 235000021318 Calcifediol Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000003880 Calendula Nutrition 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- OLUNPKFOFGZHRT-YGCVIUNWSA-N Naftifine hydrochloride Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OLUNPKFOFGZHRT-YGCVIUNWSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- CANCCLAKQQHLNK-LSDHHAIUSA-N O-[[(1R,8S)-4-tricyclo[6.2.1.02,7]undeca-2(7),3,5-trienyl]] N-methyl-N-(3-methylphenyl)carbamothioate Chemical compound CN(C(=S)Oc1ccc2[C@H]3CC[C@H](C3)c2c1)c1cccc(C)c1 CANCCLAKQQHLNK-LSDHHAIUSA-N 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical class NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
- 229920001363 Polidocanol Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 244000305267 Quercus macrolepis Species 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- OFUHPGMOWVHNPN-QWZFGMNQSA-N [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] (9z,12z)-octadeca-9,12-dienoate Chemical compound O1[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CCC2=C(C)C(OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)=C(C)C(C)=C21 OFUHPGMOWVHNPN-QWZFGMNQSA-N 0.000 description 1
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- VWXAJKFSYJFBIW-UHFFFAOYSA-N acridine-3,6-diamine;10-methylacridin-10-ium-3,6-diamine;chloride;trihydrochloride Chemical compound Cl.Cl.Cl.[Cl-].C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21.C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 VWXAJKFSYJFBIW-UHFFFAOYSA-N 0.000 description 1
- 229960000266 acriflavinium chloride Drugs 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960002535 alfacalcidol Drugs 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- XZKWIPVTHGWDCF-KUZYQSSXSA-N amorolfine hydrochloride Chemical compound Cl.C1=CC(C(C)(C)CC)=CC=C1CC(C)CN1C[C@@H](C)O[C@@H](C)C1 XZKWIPVTHGWDCF-KUZYQSSXSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940089116 arnica extract Drugs 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 229960004754 astemizole Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 229960001574 benzoxonium chloride Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 229940073609 bismuth oxychloride Drugs 0.000 description 1
- JAONZGLTYYUPCT-UHFFFAOYSA-K bismuth subgallate Chemical compound OC(=O)C1=CC(O)=C2O[Bi](O)OC2=C1 JAONZGLTYYUPCT-UHFFFAOYSA-K 0.000 description 1
- 229960000199 bismuth subgallate Drugs 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- MXJWRABVEGLYDG-UHFFFAOYSA-N bufexamac Chemical compound CCCCOC1=CC=C(CC(=O)NO)C=C1 MXJWRABVEGLYDG-UHFFFAOYSA-N 0.000 description 1
- 229960000962 bufexamac Drugs 0.000 description 1
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 description 1
- 229960004361 calcifediol Drugs 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000010627 cedar oil Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 235000019480 chamomile oil Nutrition 0.000 description 1
- 239000010628 chamomile oil Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960003749 ciclopirox Drugs 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 239000010639 cypress oil Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- PCSWXVJAIHCTMO-UHFFFAOYSA-P dequalinium Chemical class C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 PCSWXVJAIHCTMO-UHFFFAOYSA-P 0.000 description 1
- 239000003241 dermatological agent Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 description 1
- 229960002311 dithranol Drugs 0.000 description 1
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000020694 echinacea extract Nutrition 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 229960001588 ethacridine Drugs 0.000 description 1
- CIKWKGFPFXJVGW-UHFFFAOYSA-N ethacridine Chemical compound C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 CIKWKGFPFXJVGW-UHFFFAOYSA-N 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- OMRDZQXXMYCHBU-UHFFFAOYSA-N ethanol;propan-1-ol Chemical compound CCO.CCCO OMRDZQXXMYCHBU-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 1
- 229940031016 ethyl linoleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229960001274 fenticonazole Drugs 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- XLYMOEINVGRTEX-UHFFFAOYSA-N fumaric acid monoethyl ester Natural products CCOC(=O)C=CC(O)=O XLYMOEINVGRTEX-UHFFFAOYSA-N 0.000 description 1
- NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 239000010460 hemp oil Substances 0.000 description 1
- 229960004867 hexetidine Drugs 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- VRWKTAYJTKRVCU-UHFFFAOYSA-N iron(6+);hexacyanide Chemical compound [Fe+6].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] VRWKTAYJTKRVCU-UHFFFAOYSA-N 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 229960004849 isoconazole Drugs 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940099367 lanolin alcohols Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000008308 lipophilic cream Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- QUIOHQITLKCGNW-TYYBGVCCSA-L magnesium;(e)-but-2-enedioate Chemical compound [Mg+2].[O-]C(=O)\C=C\C([O-])=O QUIOHQITLKCGNW-TYYBGVCCSA-L 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WTTJVINHCBCLGX-NQLNTKRDSA-N methyl linoleate Chemical group CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC WTTJVINHCBCLGX-NQLNTKRDSA-N 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940074369 monoethyl fumarate Drugs 0.000 description 1
- NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 description 1
- 229940005650 monomethyl fumarate Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 230000009701 normal cell proliferation Effects 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960004031 omoconazole Drugs 0.000 description 1
- JMFOSJNGKJCTMJ-ZHZULCJRSA-N omoconazole Chemical compound C1=CN=CN1C(/C)=C(C=1C(=CC(Cl)=CC=1)Cl)\OCCOC1=CC=C(Cl)C=C1 JMFOSJNGKJCTMJ-ZHZULCJRSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- BAINIUMDFURPJM-UHFFFAOYSA-N oxatomide Chemical compound O=C1NC2=CC=CC=C2N1CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BAINIUMDFURPJM-UHFFFAOYSA-N 0.000 description 1
- 229960002698 oxatomide Drugs 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- BWOROQSFKKODDR-UHFFFAOYSA-N oxobismuth;hydrochloride Chemical compound Cl.[Bi]=O BWOROQSFKKODDR-UHFFFAOYSA-N 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960001179 penciclovir Drugs 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 229960002226 polidocanol Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- PXGPLTODNUVGFL-JZFBHDEDSA-N prostaglandin F2beta Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-JZFBHDEDSA-N 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- 229960005038 quinisocaine Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 239000012487 rinsing solution Substances 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 235000019294 sodium fumarate Nutrition 0.000 description 1
- 229940023144 sodium glycolate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 125000005480 straight-chain fatty acid group Chemical group 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000011269 tar Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- 229940111630 tea tree oil Drugs 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- SLYPOVJCSQHITR-UHFFFAOYSA-N tioxolone Chemical compound OC1=CC=C2SC(=O)OC2=C1 SLYPOVJCSQHITR-UHFFFAOYSA-N 0.000 description 1
- 229960003070 tioxolone Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229960003916 tolciclate Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 229940098697 zinc laurate Drugs 0.000 description 1
- GPYYEEJOMCKTPR-UHFFFAOYSA-L zinc;dodecanoate Chemical compound [Zn+2].CCCCCCCCCCCC([O-])=O.CCCCCCCCCCCC([O-])=O GPYYEEJOMCKTPR-UHFFFAOYSA-L 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
Abstract
Description
Gegenstand der vorliegenden Erfindung sind wasserhaltige Hautschutzpräparate zur Prävention von Hautschäden.The present invention relates to water-containing skin protection preparations for the prevention of Skin damage.
Die Zahl der Dermatosen und Hautallergien nimmt ständig zu. Ein häufiger Grund sind z. B. Feucht raumarbeitsplätze, an denen die Haut der Berufstätigen insbesondere wässerigen Arbeitsstoffen ausgesetzt ist. Diese und andere äußerlich einwirkende Stoffe greifen dabei die Barriereschichten der Haut an.The number of dermatoses and skin allergies is constantly increasing. A common reason are e.g. B. Moist space workplaces where the skin of the working person is particularly watery is exposed. These and other external substances attack the barrier layers of the Skin.
Die Barriereschichten bestehen neben anderen Bestandteilen aus Ceramiden, Cholesterin, Fettsäuren und Glyceriden (Kosmetik, Herausgeber W. Umbach, Georg Thieme Verlag, Stuttgart 1995, S. 27); sie sind in der Hornschicht, dem obersten Teil der Epidermis, lokalisiert. Die Barriereschichten werden sowohl durch wässerige als auch durch ölige Stoffe oder Stoffgemische mehr oder weniger gestört oder zerstört. Als Folge einer Barrierestörung nimmt in der Regel der transepidermale Wasserverlust (TEWL) der Haut zu. Es kann zu Rötungen kommen. Die Hautfeuchte nimmt ab. Die Haut trocknet aus, wird rauh und rissig. Die Penetration von irritierenden, allergisierenden Stoffen und pathogenen oder fakultativ pathogenen Keimen wird erleichtert. Ekzeme, Dermatosen und andere Hautkrankheiten können entstehen (H. Lautenschläger, Mineralöltechnik 1996, 6).The barrier layers consist, among other components, of ceramides, cholesterol and fatty acids and glycerides (cosmetics, editor W. Umbach, Georg Thieme Verlag, Stuttgart 1995, p. 27); they are localized in the horny layer, the uppermost part of the epidermis. The barrier layers will more or less disturbed by both aqueous and oily substances or mixtures of substances or destroyed. As a result of a barrier disorder, the transepidermal water loss usually increases (TEWL) of the skin. There may be redness. The skin moisture decreases. The skin dries out, becomes rough and cracked. The penetration of irritant, allergic and pathogenic substances or facultatively pathogenic germs is relieved. Eczema, dermatoses and other skin diseases can arise (H. Lautenschläger, Mineralöltechnik 1996, 6).
Es gibt eine Reihe von Möglichkeiten, die Haut gegen Arbeitsstoffe und andere äußerliche Stoffe zu schützen. Der einfachste Schutz sind z. B. für die Hände Handschuhe, die jedoch den Nachteil haben, daß die Haut schwitzt und von innen her quillt. Außerdem geht mit Handschuhen ein hohes Maß an Sensibilität bei der Arbeit verloren. Okklusiv wirkende konventionelle Hautschutzpräparate auf der Basis von Mineralölprodukten, Silikonen und abdeckend wirkenden Fetten und Ölen haben bekannt lich den Nachteil, daß die Haut wie bei einem Handschuh von innen her quillt und die hauteigene Synthese barriereaktiver Stoffe vermindert wird (K. R. Feingold, Cosmetics & Toiletries 112 (7), 49-59 (1997)).There are a number of ways the skin can work against agents and other external substances too protect. The simplest protection is e.g. B. gloves for the hands, but they have the disadvantage that the skin sweats and swells from the inside. In addition, gloves are a high standard Lost sensitivity at work. Conventional skin protection products with an occlusive effect on the The basis of mineral oil products, silicones and covering greases and oils have been known Lich the disadvantage that the skin swells from the inside like a glove and the skin's own Synthesis of barrier-reactive substances is reduced (K.R. Feingold, Cosmetics & Toiletries 112 (7), 49-59 (1997)).
Konventionelle Hautschutzmittel sind gewöhnlich Öl-in-Wasser(O/W)- oder Wasser-in-Öl(W/O)- Cremes. Sie sind überwiegend okklusiv wirksam und berücksichtigen in der Regel nur den Schutz vor äußerlich einwirkenden Stoffen, aber nicht spezielle Hautdispositionen. So benötigen z. B. Menschen, die eine Disposition zur atopischen Dermatitis (Neurodermitis), Schuppenflechte (Psoriasis), Ichthiosis, Urticaria (Nesselsucht) oder Dyskeratose haben, oder auch Menschen, die eine Veranlagung zu Hautunreinheiten oder Akne haben, Präparate, die in der Lage sind, die Haut gleichzeitig gegen die Einwirkung äußerlicher (Schad-)Stoffe zu schützen sowie endogen bedingte Hautschäden zu verhindern. Dabei ist es notwendig, die Barriere zu stabilisieren und gegebenenfalls auch zu verstärken. Schutz bedeutet aber auch, daß die Haut für den Fall des gewünschten Zusatzes eines dermatologisch wirksamen Cremebestandteils von dessen gegebenenfalls vorhandenen Nebenwirkungen geschützt wird. Dementsprechend muß eine gleichmäßige und verträgliche Penetration einstellbar sein. Es sind daher Hautschutzpräparate erforderlich, die hinsichtlich ihrer Zusammensetzung sowohl der jeweiligen Haut, deren Zustand und Disposition sowie den von außen einwirkenden Stoffen inklusive dermatologischen Wirkstoffen angepaßt werden können. Wünschenswert sind auch Basiscremes, die durch Zusatz individueller Wirkstoffe vor Ort auf den einzelnen Hauttyp einstellbar sind.Conventional skin protection products are usually oil-in-water (O / W) - or water-in-oil (W / O) - Creams. They are mostly occlusive and usually only take protection against external substances, but not special skin dispositions. So need z. B. people which are predisposed to atopic dermatitis (neurodermatitis), psoriasis (psoriasis), Ichthiosis, urticaria (hives) or dyskeratosis, or people who have one Are predisposed to blemishes or acne, preparations that are able to skin at the same time protect against the effects of external (harmful) substances and endogenously caused To prevent skin damage. It is necessary to stabilize the barrier and if necessary also reinforce. Protection also means that the skin in the event of the desired addition a dermatologically active cream component of any present Side effects is protected. Accordingly, an even and tolerable Penetration can be adjustable. Skin protection preparations are therefore necessary with regard to their Composition of both the respective skin, its condition and disposition as well as that from the outside acting substances including dermatological agents can be adapted. Base creams are also desirable, which are added to the skin by adding individual active ingredients individual skin type are adjustable.
Dabei müssen die Präparate der Haut Fettstoffe zuführen, dürfen aber nach der Applikation nicht fetten. D. h. sie sollten frei sein von Stoffen, die an der Hautoberfläche verbleiben und bei der Berüh rung von Gegenständen Rückstände hinterlassen. Stoffe, die mit diesen Nachteilen behaftet sind, sind z. B. Mineralölbestandteile wie Vaseline, Paraffinöle sowie Ozokerit (Erdwachs), aber z. B. auch polymere α-Olefine und Silikone. Solche Stoffe sind u. a. im betrieblichen Hautschutz völlig un geeignet.The preparations have to supply fatty substances to the skin, but are not allowed after the application fat. I.e. they should be free of substances that remain on the skin surface and in contact with the skin of objects. Substances that have these disadvantages are e.g. B. mineral oil components such as petroleum jelly, paraffin oils and ozokerite (earth wax), but z. Belly polymeric α-olefins and silicones. Such substances are a. completely un in company skin protection suitable.
Darüber hinaus sollten Hautschutzpräparate frei sein von den Alkanolaminen: Triethanolamin, Diethanolamin und Ethanolamin sowie deren Salzen (siehe Einschränkungen der deutschen Kosmetikverordnung, BGBI. I, Nr. 67, S. 2410 v. 13.10.97, hinsichtlich der Nitrosaminproblematik und der deutschen Technischen Regel für Gefahrstoffe, TRGS 540, Bundesarbeitsblatt 12/1997, hinsichtlich der Möglichkeit von Sensibilisierungen). Dagegen können geringe Zusätze physiologisch unbedenklicher und dermatologisch sicherer Amine wie z. B. Trometamol, Arginin und Lysin, die neben den üblichen Alkalihydroxiden der Einstellung des pH's der Hautschutzpräparate dienen, toleriert werden.In addition, skin protection preparations should be free from the alkanolamines: triethanolamine, Diethanolamine and ethanolamine and their salts (see restrictions of the German Cosmetics regulation, BGBI. I, No. 67, p. 2410 v. 13.10.97, regarding the nitrosamine problem and the German Technical Rule for Hazardous Substances, TRGS 540, Federal Worksheet 12/1997, regarding the possibility of sensitization). In contrast, small additions can be physiological safe and dermatologically safe amines such as B. trometamol, arginine and lysine, the In addition to the usual alkali hydroxides, the pH of the skin protection preparations are used, be tolerated.
Die Hautschutzpräparate sollten frei sein von konventionellen Emulgatoren wie z. B. Ethoxilaten, die für ihre Reizungen und/oder Comedonenbildung unter normalen Verhältnissen oder unter besonderen Bedingungen wie der UV-Bestrahlung bekannt sind (G. Dahms, Parfümerie und Kosmetik 76, 426-431 (1995)).The skin protection preparations should be free from conventional emulsifiers such as. B. ethoxylates, the for their irritation and / or comedone formation under normal conditions or under special ones Conditions such as UV radiation are known (G. Dahms, Perfumery and Cosmetics 76, 426-431 (1995)).
Weiter sollten Konservierungsmittel ausgeschlossen werden, da diese Stoffe in der Regel sensibilisie rende und/oder irritierende Eigenschaften besitzen. Preservatives should also be excluded, as these substances are generally sensitive rende and / or irritating properties.
Die Hautschutzpräparate müssen auch trotz des Fehlens typisch wasserabweisender Stoffe wie Vaseline, Paraffinöle und Silikonöle über eine ausreichende Wasserresistenz (Wasserfestigkeit) verfügen. Die Wasserfestigkeit bezieht sich dabei vor allem auf die für die ursächliche Wirkung der Hautschutzpräparate verantwortlichen barrierestabilisierenden Inhaltsstoffe.The skin protection preparations must also, despite the lack of typical water-repellent substances such as Vaseline, paraffin oils and silicone oils have sufficient water resistance (water resistance) feature. The water resistance relates primarily to the causal effect of the Skin protection products responsible barrier-stabilizing ingredients.
Der Zusatz physiologischer verträglicher Feuchthaltesubstanzen sollte ein Bestandteil des Haut schutzes hinsichtlich der Verhinderung von Hautrauhig- und Hautrissigken sowie des Schutzes vor lipophilen Schadstoffen sein.The addition of physiologically compatible moisturizing substances should be part of the skin protection with regard to the prevention of skin roughness and skin cracks as well as the protection against be lipophilic pollutants.
Es hat sich nun überraschend gezeigt, daß die Gesamtheit der genannten Forderungen an Haut schutzpräparate auf der Basis von hydriertem (gesättigtem) Phosphatidylcholin (PC-H) realisiert werden kann.It has now surprisingly been found that all of the skin requirements mentioned Protective preparations based on hydrogenated (saturated) phosphatidylcholine (PC-H) can be.
Hydriertes Phosphatidylcholin ist ein typischer barrierestabilisierender Stoff, der in der Regel
ursprünglich aus dem Phosphatidylcholin der Sojabohne stammt, das aulkonzentriert und nachfolgend
hydriert wird. Die Fettsäurebesetzung eines solchen Phosphatidylcholins besteht gemäß Formel I
überwiegend aus Stearinsäure und Palmitinsäure (n = 14, 16):
Hydrogenated phosphatidylcholine is a typical barrier stabilizing substance, which usually originates from the soybean phosphatidylcholine, which is concentrated and subsequently hydrogenated. According to formula I, the fatty acid occupancy of such a phosphatidylcholine consists predominantly of stearic acid and palmitic acid (n = 14, 16):
Dies ist insofern völlig neu, da ungesättigtes Phosphatidylcholin (PC) insbesondere in seiner lipo somalen Form ein effektiver Penetrationsverstärker (K. Egbaria und N. Weiner, Cosmetics & Toiletries 106 (3), 79-93 (1991)) ist. PC kann zwar als Bilayerquelle in Hautpflegemitteln geschädigte Lipid doppelschichten der Hornschicht wieder aufbauen (DE 40 21 082), es erzeugt aber aufgrund seiner niedrigen Phasenumwandlungstemperatur in wässeriger Umgebung nach topischer Applikation in der Hornschicht sehr fluide Lipiddoppelschichten. Diese sind naturgemäß für Hautschutzpräparate kontraindiziert, d. h. nicht geeignet, da sie für äußerlich einwirkende (Schad-) Stoffe außerordentlich gut durchlässig sind. Daher werden Hautpflegemittel und z. B. Mittel zur Behandlung der Psoriasis (DE 40 21 084) auf der Basis von PC, wo die Penetration z. B. von Fumarsäure im Vordergrund steht, in der Regel ohne Konservierungsmittel hergestellt, um verstärkte Irmationen und Sensibilisierungen zu vermeiden. Die Penetrationsverstärkung wird auch bei liposomalen Bädern in Verbindung mit medizinischen und kosmetischen Wirkstoffen genutzt (DE 40 21 083). Hautschutzpräparate auf der Basis von PC sind daher nicht sinnvoll, da sie die Hautbarriere nicht in ausreichendem Maß gegen das Eindringen äußerlicher Stoffe stabilisieren können.This is completely new in that unsaturated phosphatidylcholine (PC), especially in its lipo somalen form an effective penetration enhancer (K. Egbaria and N. Weiner, Cosmetics & Toiletries 106 (3), 79-93 (1991)). Although PC can act as a bilayer source in lipid damaged skin care products Reconstruct double layers of the horny layer (DE 40 21 082), but it creates due to its low phase transition temperature in an aqueous environment after topical application in the Horny layer of very fluid lipid bilayers. These are naturally for skin protection products contraindicated, d. H. not suitable, as it is extraordinary for externally acting (harmful) substances are well drained. Therefore skin care products and z. B. Treatments for psoriasis (DE 40 21 084) based on PC, where the penetration z. B. of fumaric acid is in the foreground, usually made without preservatives to increase irritation and sensitization to avoid. The penetration enhancement is also associated with liposomal baths medical and cosmetic active ingredients used (DE 40 21 083). Skin protection products on the The basis of PC is therefore not useful since it does not sufficiently counter the skin barrier can stabilize the penetration of external substances.
Dagegen hat PC-H eine ausgeprägte barrierestabilisierende Wirkung, die vor unspezifischen Barriere schäden und darüber hinaus vor spezifischen Barriereschäden, wie sie z. B. bei Neurodermnis und Psoriasis auftreten, schützt. Darüber hinaus hat sich überraschend herausgestellt, daß PC-H auch präventiv vor Akne schützen kann. Bekanntlich wird nur PC aufgrund seines Gehaltes an essentiellen Fettsäuren zur Behandlung der Akne und unreiner Haut empfohlen (WO 94/03156, DE 44 04 086, DE 44 03 989). Dadurch ist es möglich, mit jeweils einem einzigen und von konventionellen Emulgatoren gänzlich freien Präparat sowohl vor Dermatosen und Ekzemen, die durch Schadstoffe, insbesondere auch Arbeitsstoffe, ausgelöst werden, als auch bei entsprechender Disposition vor endogen bedingten Hautschäden zu schützen.In contrast, PC-H has a pronounced barrier-stabilizing effect, that of unspecific barriers damage and, moreover, specific barrier damage such as e.g. B. in neuroderma and Psoriasis occurs, protects. In addition, it has surprisingly been found that PC-H too preventively protect against acne. As is well known, only PC is due to its essential content Fatty acids recommended for the treatment of acne and blemished skin (WO 94/03156, DE 44 04 086, DE 44 03 989). This makes it possible to use single emulsifiers and conventional emulsifiers Completely free preparation from both dermatoses and eczema caused by pollutants, in particular also working materials are triggered, as well as with appropriate disposition to endogenous conditions To protect skin damage.
Es ist in diesem Zusammenhang anzumerken, daß die in den genannten Patenten beschriebenen Aknemittel nicht nur wegen der alleinigen PC-Basis, sondern auch aufgrund des in der Regel in den Präparaten enthaltenen Lösungsmittels für den Einsatz als Hautschutzmittel ungeeignet sind; auch die in DE 40 21 083 genannten PC-haltigen Badeöle sind zwar für Personen, die eine Disposition zu Allergien, Psoriasis, Neurodermitis oder Ichthiose zeigen, geeignet, lassen sich aber aus den oben genannten Gründen ebenfalls nicht als Hautschutzpräparate einsetzen. DE 40 21 084 beschreibt topische Arzneimittel zur Behandlung der Psoriasis und verwandter Hautkrankheiten, DE 40 21 082 Hautbehandlungsmittel mit hohen Lipidgehalten unter Verwendung eines Bilayer enthaltenden Systems, Salzen organischer Säuren, Alkohol und Stabilisator. In diesen beiden Patenten werden unter anderem auch hydrierte Phosphatidylcholine in ihrer bekannten Funktion als Bilayerquelle, aber keine Hautschutzpräparate erwähnt, wobei in der DE 40 21 082 auch ausdrücklich Seifen als Hauptkomponenten eingesetzt werden. Die emulgatorisch wirksamen Seifen wandeln sich unter dem Einfluß des Alkalineutralisationsverhaltens der Haut erst allmählich in die freien Säuren um und sind daher für den gewerblichen Alltag, bei dem es auf den sofortigen Eintritt des Hautschutzes ankommt, weniger geeignet.In this connection, it should be noted that those described in the patents mentioned Acne remedies not only because of the sole PC base, but also because of the usually in the Preparations containing solvents are unsuitable for use as skin protection agents; also the PC-containing bath oils mentioned in DE 40 21 083 are for people who have a disposition too Allergies, psoriasis, neurodermatitis or ichthiosis show, suitable, but can be from the above reasons mentioned also do not use as skin protection products. DE 40 21 084 describes topical drugs for the treatment of psoriasis and related skin diseases, DE 40 21 082 Skin treatment agent with high lipid contents using a bilayer containing Systems, salts of organic acids, alcohol and stabilizer. These two patents are among others also hydrogenated phosphatidylcholines in their known function as a bilayer source, however no skin protection preparations mentioned, DE 40 21 082 also expressly describes soaps as Main components are used. The emulsifying soaps change under the Influence of the alkaline neutralization behavior of the skin only gradually changes into the free acids therefore for everyday business, where immediate protection of the skin is essential, less suitable.
Die Hautbarriere wird durch die PC-H-haltigen erfindungsgemäßen Hautschutzpräparate derart stabilisiert, daß sich nach der Applikation der Hautschutzpräparate der in einem normalen Bereich liegende TEWL nur geringfügig ändert, wenn äußerliche Stoffe auf die Haut einwirken, oder ein bereits erhöhter TEWL normalisiert wird. Der so erhaltene Schutz zeichnet sich darüber hinaus durch eine hohe Wasserresistenz und Schweißfestigkeit aus.The skin barrier is made this way by the skin protection preparations according to the invention containing PC-H stabilizes that after the application of the skin protection products in a normal range lying TEWL changes only slightly if external substances act on the skin, or one already increased TEWL is normalized. The protection obtained in this way is also characterized by a high water resistance and sweat resistance.
Ein weiteres Charakteristikum der erfindungsgemäßen Hautschutzpräparate sind Triglyceride, die mit gleicher oder vergleichbarer Struktur auch im natürlichen Sebum vorkommen. Vorzugsweise handelt es sich um mittelkettige Triglyceride (MCT). MCT können aufgrund ihrer Struktur das natürliche Sebum zum Teil substituieren bzw. sind mit dem Sebum außerordentlich verträglich. MCT haben außerdem den Vorteil, lipophile Schutz- und Wirkstoffe inkorporieren zu können sowie schnell in die Haut einzuziehen und somit nicht zu fetten. Aufgrund der PC-H-Eigenschaften benötigen die Präparate keine zusätzlichen Emulgatoren und verfügen ohne Zusätze von Mineralölprodukten, synthetischen Paraffinen oder Silikonen über eine hohe Wasserfestigkeit. Die amphiphile Struktur des PC-H erlaubt den Einsatz der erfindungsgemäßen Hautschutzpräparate sowohl gegenüber den oben genannten Barriere- und Hautschäden als auch gegenüber wässerigen und öligen (Schad-) Stoffen. Bei Hautschutzpräparaten gegen spezielle ölige Schadstoffe kann der MCT-Anteil der Hautschutzpräparate gegebenenfalls reduziert werden. Ein weiterer Vorteil der amphiphilen Struktur des PC-H und der Abwesenheit konventioneller Emulgatoren in den Hautschutzpräparaten ist die vergleichsweise geringe Quellung der Haut bei der Einwirkung wässeriger Medien (vgl. entsprechende Messungen bei Körperreinigungsmitteln: U. Zeidler, Ärztliche Kosmetologie 19, 208-219 (1989)); damit ergeben sich auch günstige Gebrauchseigenschaften im gewerblichen Schutz der Hände, wenn zeitweise mit Handschuhen gearbeitet wird.Another characteristic of the skin protection preparations according to the invention are triglycerides, which with same or comparable structure also occur in natural sebum. Preferably acts medium-chain triglycerides (MCT). Due to their structure, MCT can do the natural thing Some substitute sebum or are extremely compatible with sebum. Have MCT also the advantage of being able to incorporate lipophilic protective and active substances and quickly into the To absorb skin and therefore not to grease. Due to the PC-H properties they need Preparations do not contain any additional emulsifiers and have no added petroleum products, synthetic paraffins or silicones with high water resistance. The amphiphilic structure of the PC-H allows the skin protection preparations according to the invention to be used both compared to the above mentioned barrier and skin damage as well as against aqueous and oily (harmful) substances. In the case of skin protection preparations against special oily pollutants, the MCT portion of the Skin protection products may be reduced. Another advantage of the amphiphilic structure of PC-H and the absence of conventional emulsifiers in skin protection products is the comparatively little swelling of the skin when exposed to aqueous media (cf. corresponding Measurements for body cleansers: U. Zeidler, medical cosmetology 19, 208-219 (1989)); in order to there are also favorable usage properties in the commercial protection of the hands, if working with gloves at times.
Die erfindungsgemäßen Hautschutzpräparate enthalten darüber hinaus Salze, die in der Lage sind, den für eine gesunde Haut charakteristischen Mineralsalzgehalt zu stabilisieren oder zu verstärken. Bekanntlich ist der Mineralsalzgehalt ein wichtiger regulierender Faktor sowohl für die Hautfeuchte als auch für eine normale Zellproliferation und Zelldifferenzierung sowie der damit zusammenhängenden Synthese epidermaler, barriereaktiver Lipide (K. R. Feingold, Cosmetics & Toiletries 112 (7), 49-59 (1997)).The skin protection preparations according to the invention furthermore contain salts which are able to Stabilize or strengthen the mineral salt content that is characteristic of healthy skin. The mineral salt content is known to be an important regulating factor for both the skin moisture and also for normal cell proliferation and cell differentiation and the related Synthesis of epidermal, barrier-reactive lipids (K.R. Feingold, Cosmetics & Toiletries 112 (7), 49-59 (1997)).
Die erfindungsgemäßen Hautschutzpräparate enthalten physiologisch verträgliche Feuchthaltesub stanzen auf der Basis von Polyolen und/oder Harnstoff. Diese Substanzen binden Wasser und haben eine hohe Wirksamkeit hinsichtlich der Verhinderung von Hautrauhigkeit und -rissigkeit und ins besondere des Schutzes vor öligen (lipophilen) Stoffen.The skin protection preparations according to the invention contain physiologically compatible moisturizing substances punch on the basis of polyols and / or urea. These substances bind and have water high effectiveness in preventing skin roughness and cracking and ins special protection against oily (lipophilic) substances.
Die erfindungsgemäßen Hautschutzpräparate unterscheiden sich aufgrund ihrer Zusammensetzung grundlegend von den bisher bekannten konventionellen O/W- und W/O-Emulsionen. Während O/W- Emulsionen in der Regel gegen ölige Stoffe schützen und W/O gegen wässerige Stoffe schützen, können die erfindungsgemäßen Hautschutzpräparate sowohl gegen ölige als auch gegen wässerige Stoffe sowie deren Gemische schützen. Der Grund ist die sehr geringe Löslichkeit des hydrierten Phosphatidylcholins in öligen und wässerigen Medien. Es gleicht in dieser Eigenschaft sehr stark den barriereaktiven Ceramiden. Der Hautschutz erstreckt sich auch auf Stäube, hohe und niedrige Luft feuchtigkeit und Aerosole. Die Hautschutzpräparate zeichnen sich durch eine feine Dispersität aus und sind in der Regel nicht liposomal aufgebaut.The skin protection preparations according to the invention differ in their composition fundamentally from the previously known conventional O / W and W / O emulsions. During E / W Usually protect emulsions against oily substances and protect W / O against aqueous substances, The skin protection preparations according to the invention can be used against both oily and aqueous Protect substances and their mixtures. The reason is the very low solubility of the hydrogenated Phosphatidylcholins in oily and aqueous media. In this capacity it is very similar to that barrier-reactive ceramides. The skin protection also extends to dusts, high and low air moisture and aerosols. The skin protection preparations are characterized by a fine dispersity and are usually not liposomal.
Die erfindungsgemäßen Hautschutzpräparate können dermatologische und kosmetische Wirkstoffe enthalten. Wirkstoffe haben den Sinn, die erfindungsgemäßen hautschützenden Eigenschaften noch zu verstärken oder zu ergänzen. Die Wirkstoffe sind insbesondere reiz- und entzündungshemmender Natur. Bei Dispositionen zu Neurodermitis-, Urticaria-, Psoriasis- oder Ichthiose-artigen Hautschäden sind juckreizhemmende und lokalananästhetisch wirkende Stoffe hilfreich, um vor entsprechenden manuellen Verletzungen durch Kratzen von vornherein zu schützen. Als Wirkstoffe werden aber auch z. B. Stoffe verstanden, die die Haut verstärkt vor dem Eindringen schädlicher Schwermetallionen (Nickel, Kobalt, Kupfer etc.) schützen. Die Wirkung dieser Wirkstoffe beruht in der Regel auf der Bindung der Schwermetalle durch Komplexierung oder auf einer zusätzlichen Verstärkung der Barriere. Weitere geeignete zusätzliche Wirkstoffe sind hautschützende Lipide und Wachse, Vitamine und Provitamine, Antimykotika, antiinflammatorisch wirkende Stoffe, Ilmmunsuppressiva, Antiinfektiva, Antiseptika, Virustatika, Adstringentien, Pflanzen- und Hefeextrakte, Pflanzenöle mit spezifischen Wirkungen oder einem hohen Gehalt an hochungesättigten (essentiellen) Fettsäuren, barriere stabilisierende Säuren, abdeckende Stoffe und Pigmente sowie Einzelstoffe mit speziellen Wirkungen (z. B. bei Akne). The skin protection preparations according to the invention can be dermatological and cosmetic active ingredients contain. Active ingredients have the sense, the skin-protecting properties according to the invention still to reinforce or supplement. The active ingredients are particularly anti-irritant and anti-inflammatory Nature. With dispositions to skin dermatitis, urticaria, psoriasis or ichthiosis-like damage antipruritic and local anesthetic substances are helpful to prevent corresponding to protect manual injuries from scratching from the outset. But also as active ingredients e.g. B. understood substances that reinforce the skin against the penetration of harmful heavy metal ions Protect (nickel, cobalt, copper, etc.). The effect of these active ingredients is usually based on the Binding of the heavy metals by complexation or on an additional reinforcement of the Barrier. Other suitable additional active ingredients are skin-protecting lipids and waxes, vitamins and provitamins, antifungals, anti-inflammatory substances, immunosuppressants, anti-infectives, Antiseptics, antivirals, astringents, plant and yeast extracts, vegetable oils with specific Effects or a high content of highly unsaturated (essential) fatty acids, barrier stabilizing acids, covering substances and pigments as well as single substances with special effects (e.g. with acne).
Ein besonderer Vorteil von Hautschutzpräparaten ist die Tatsache, daß in diesen Präparaten auch empfindliche Wirkstoffe, wie Vitamine und ungesättigte Naturprodukte (z. B. Nachtkerzenöl) durch die Phosphatidylcholine ähnlich wie in liposomalen Präparaten geschützt werden. Diese Stoffe werden in den erfindungsgemäßen Hautschutzpräparaten deutlich langsamer abgebaut bzw. oxidativ verändert. Die Dosierungen entsprechender Hilfsstoffe können infolgedessen vermindert oder diese Stoffe können ganz eliminiert werden.A particular advantage of skin protection preparations is the fact that in these preparations too sensitive active ingredients, such as vitamins and unsaturated natural products (e.g. evening primrose oil) through the Phosphatidylcholines are protected similarly as in liposomal preparations. These substances are in the skin protection preparations according to the invention are broken down much more slowly or are oxidatively changed. As a result, the dosages of appropriate auxiliaries can be reduced or these substances can be eliminated entirely.
Die Hautschutzpräparate können mit üblichen, dem Fachmann bekannten Mischwerkzeugen gemischt und nachfolgend mit einem Leitstrahlmischer, Rotorstatorgerät, Hochdruckhomogenisator, Dissolver oder anderen ähnlichen Geräten homogenisiert werden. Die Herstellung wird in einem Beispiel erläutert. Die Hautschutz-Dispersionen zeichnen sich aufgrund ihrer spezifischen Zusammensetzung dadurch aus, daß dermatologische oder kosmetische Wirkstoffe entweder direkt oder auch später ohne Stabiltätsverlust durch einen einfachen Rührvorgang kalt eingearbeitet werden können. Dabei ist es gleichgültig, ob es sich um wässerige oder ölige Wirkstoffe oder Wirkstoffmischungen handelt. Dies unterscheidet sie vorteilhaft von konventionellen Emulsionen, aber auch von liposomalen Formulierungen, die bei dieser Vorgehensweise in der Regel keine zusätzlichen Stoffe aufnehmen oder mehr oder weniger instabil werden. Die erfindungsgemäßen Hautschutzpräparate lassen sich daher vor Ort leicht den Erfordernissen einer individuellen Haut anpassen.The skin protection preparations can be mixed with conventional mixing tools known to those skilled in the art and subsequently with a guide beam mixer, rotor stator device, high pressure homogenizer, dissolver or other similar devices can be homogenized. The manufacture is in an example explained. The skin protection dispersions stand out due to their specific composition characterized in that dermatological or cosmetic active ingredients either directly or later can be cold worked in without loss of stability by a simple stirring process. It is it does not matter whether it is aqueous or oily active substances or active substance mixtures. This distinguishes them advantageously from conventional emulsions, but also from liposomal ones Formulations that generally do not absorb any additional substances with this procedure or become more or less unstable. The skin protection preparations according to the invention can be therefore easily adapt to the requirements of an individual skin on site.
Zusammengefaßt bestehen die erfindungsgemäßen Hautschutzpräparate aus:
In summary, the skin protection preparations according to the invention consist of:
- 1. hydriertem (gesättigtem) Phosphatidylcholin (PC-H) mit einem Zusatz von1. hydrogenated (saturated) phosphatidylcholine (PC-H) with the addition of
- 2. mittelkettigen Triglyceriden,2. medium chain triglycerides,
- 3. Salzen,3. Salting,
- 4. Feuchthaltesubstanzen,4. moisturizing substances,
- 5. Wirkstoffen,5. active substances,
- 6. Wasser.6. Water.
So können in den erfindungsgemäßen Hautschutzpräparaten z. B. die folgenden Inhaltsstoffe verar
beitet werden:
For example, in the skin protection preparations according to the invention. B. the following ingredients are processed:
- 1. Hydriertes (gesättigtes) Phosphatidylcholin (PC-H): Darunter sind Phosphatidylcholine pflanz licher, tierischer oder synthetischer Herkunft zu verstehen, deren ungesättigte veresterte Säure komponenten vollständig hydriert wurden. Selbstverständlich lassen sich gesättigte synthetische Phosphatidylcholine, die sinngemäß mit hydrierten Phosphatidylcholinen identisch sind, auch aus entsprechenden Einzelkomponenten synthetisieren. Hydrierte Phosphatidylcholine sind z. B. unter dem Namen Phospholipon 80 H, Phospholipon 90 H oder Phospholipon 100 H im Handel. Die Zahlen hinter dem Namen sind ein Maß für den Phosphatidylcholingehalt, der unter Einbeziehung anderer Handelsprodukte in der Regel zwischen 50 und 100% variieren kann. Der jeweilige Rest der Produkte besteht zum größten Teil aus bekannten (Sojaöl-)typischen Begleitphospholipiden (Phosphatidylethanolamin, Phosphatidylinositol, Lysophosphatidylcholin, Phosphatidsäure, Rest ölgehalt), die auch in hydrierter Form vorliegen. Synthetische Phosphatidylcholine sind z. B. Dipalmitoylphosphatidylcholin (DPPC) oder Distearoylphosphatidylcholin (DSPC).1. Hydrogenated (saturated) phosphatidylcholine (PC-H): Among them are phosphatidylcholine plants Licher, animal or synthetic origin to understand their unsaturated esterified acid components were completely hydrogenated. Of course, saturated synthetic Phosphatidylcholines, which are logically identical to hydrogenated phosphatidylcholines, also from synthesize corresponding individual components. Hydrogenated phosphatidylcholines are e.g. More colorful the name Phospholipon 80 H, Phospholipon 90 H or Phospholipon 100 H commercially. The Numbers behind the name are a measure of the phosphatidylcholine content, which includes other commercial products can usually vary between 50 and 100%. The rest most of the products consist of known (soybean oil) typical accompanying phospholipids (Phosphatidylethanolamine, phosphatidylinositol, lysophosphatidylcholine, phosphatidic acid, rest oil content), which are also available in hydrogenated form. Synthetic phosphatidylcholines are e.g. B. Dipalmitoylphosphatidylcholine (DPPC) or Distearoylphosphatidylcholine (DSPC).
- 2. Mittelkettige Triglyceride (MCT): Darunter sind im Rahmen der erfindungsgemäßen Hautschutz präparate mittelkettige Triglyceride oder Triglyceridmischungen zu verstehen, in denen geradkettige Fettsäuren mit Kettenlängen von C8 bis C16 mit Glycerin verestert sind. Besonders bevorzugt sind Triglyceride mit Fettsäuren C8 bis C12. Produkte dieser Art werden unter verschiedenen Namen gehandelt (z. B. Myritol 312 und 318 oder Miglyol, 810 und 812).2. Medium-chain triglycerides (MCT): Within the scope of the skin protection according to the invention, this means medium-chain triglycerides or triglyceride mixtures in which straight-chain fatty acids with chain lengths of C 8 to C 16 are esterified with glycerol. Triglycerides with fatty acids C 8 to C 12 are particularly preferred. Products of this type are traded under different names (e.g. Myritol 312 and 318 or Miglyol, 810 and 812).
- 3. Salze: Darunter sind im Rahmen der erfindungsgemäßen Hautschutzpräparate Salze des Natriums, Kaliums, Magnesiums, Calciums, Zinks und Cholins zu verstehen. Bevorzugt sind Fluoride, Chloride, Sulfate, Phosphate, 2-Aminoethylphosphate, Glycolate, Lactate, Citrate, Succinate, Malate, Fumarate, Monomethylfumarate, Monoethylfumarate, Tartrate oder deren Gemische. Die Gemische können z. B. auch natürlichen Ursprungs sein (unter anderem Meersalz unterschiedlicher Provenienz, z. B. aus dem toten Meer). Besonders bevorzugt sind Chloride, Sulfate und Fumarate des Kaliums, Natriums und Magnesiums.3. Salts: Among them are salts of the skin protection preparations according to the invention To understand sodium, potassium, magnesium, calcium, zinc and choline. Are preferred Fluorides, chlorides, sulfates, phosphates, 2-aminoethyl phosphates, glycolates, lactates, citrates, Succinate, malate, fumarate, monomethyl fumarate, monoethyl fumarate, tartrate or their Mixtures. The mixtures can e.g. B. also be of natural origin (including sea salt different provenance, e.g. B. from the Dead Sea). Chlorides are particularly preferred, Sulphates and fumarates of potassium, sodium and magnesium.
- 4. Feuchthaltesubstanzen: Darunter sind im Rahmen der erfindungsgemäßen Hautschutzpräparate physiologisch verträgliche Polyole, Harnstoff oder deren Gemische untereinander zu verstehen. Typische Vertreter sind Glykol, Propylenglykol, Butylenglykol, Pentylenglykol, Hexylenglykol, Glycerin, Inositol (Inosit), Sorbitol (Sorbit), Mannit, Palatinit, Maltodextrin, Dextrin, Cyclodextrin, Glucose, Fructose, Lactose, Mannose, Galaktose sowie andere Saccharide. Besonders bevorzugt sind Glycerin, Propylenglykol, Pentylenglykol und Harnstoff, wobei Propylenglykol aufgrund seiner partiellen penetrationsfördernden Eigenschaften in möglichst niedriger Dosierung angewandt wird.4. Moisturizing substances: These include within the scope of the skin protection preparations according to the invention understand physiologically compatible polyols, urea or mixtures thereof. Typical representatives are glycol, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, Glycerin, inositol (inositol), sorbitol (sorbitol), mannitol, palatinite, maltodextrin, dextrin, cyclodextrin, Glucose, fructose, lactose, mannose, galactose and other saccharides. Particularly preferred are glycerin, propylene glycol, pentylene glycol and urea, whereby propylene glycol due to its partial penetration-promoting properties are used in the lowest possible dosage.
-
5. Dermatologische und kosmetische Wirkstoffe der erfindungsgemäßen Hautschutzpräparate sind
hautschützende Lipide und Wachse wie z. B. Mono-, Di-, Tri- und Polyglyceride der Rizinol-, 12-
Hydroxystearin- und 11-Hydroxypalmitinsäure, Rizinusöl, gehärtetes Rizinusöl, Rizinolsäureoctyl
dodecylester, 12-Hydroxystearinsäureoctylester, Bienenwachs, Japanwachs, Carnaubawachs,
Cetylpalmitat, Kakaobutter, Jojobaöl, Sheabutter, Squalen, Squalan, Cholesterin, Cholesterylsul
fat, Phytosterole, Lanolin, Lanolinalkohole und deren Derivate, Ceramide, Sphingolipide,
Sphinganin, Sphingosin, Sphingosin-1-phosphat, Sphingomyelin, C12-C15-Alkylbenzoat, Linol
säuremethyl- und -ethylester, Linolsäure-mono-, di- und triglyceride, lsopropylmyristat, Isopropyl
palmitat sowie natürliche fette Öle, wie z. B. Avocadoöl, Weizenkeimöl, Macadamianußöl,
Aprikosenkernöl, Mandelöl, Hanföl, Leinsamenöl, Sesamöl, Olivenöl, Sonnenblumenöl, Erdnußöl
in natürlicher und hydrierter Form. Weitere Wirkstoffe können Vitamine und Provitamine
(insbesondere A, B-Komplex, C, E, D sowie deren übliche Derivate wie Vitamin A-säure, Vitamin
A-acetat, Vitamin A-palmitat, Vitamin C-palmitat, Vitamin E-acetat, -palmitat und -linoleat,
Alfacalcidol, Calcitriol, Colecalciferol, Ergocalciferol, Transcalcifediol, Calciprotriol, Calcifediol,
Vitamin D3, β-Carotin, Panthenol, Pantothensäure, Biotin), juckreizstillende Ober
flächenanästhetika (z. B. Lidocain, Benzocain, Polidocanol, 20%ige wässrige Hamstoffiösungen,
Isoprenalin, Crotamiton, Quinisocain), juckreizstillende H1-Antihistaminika (z. B. Meclozin,
Cetirizin, Promethazin, Diphenhydramin, Chlophenoxamin, Doxylamin, Pheniramin, Bromphenira
min. Dexchlorpheniramin, Bamipin, Clemastin, Dimetinden, Mebhydrolin, Loratadin, Oxatomid,
Terfenadin, Astemizol), Antimykotika (z. B. Econazol, Bifonazol, Isoconazol, Oxiconazol, Tioco
nazol, Fenticonazol, Clotrimazol, Miconazol, Ketoconazol, Itraconazol, Flucanazol, Sertaconazol,
Terbinafin, Naftifin, Omoconazol, Tolnaftat, Amorolfin, Amphotericin B, Nystatin, Natamycin,
Griseofulvin, Flucytosin, Ciclopirox, Tolciclat, Undecylensäure), antünflammatorisch wirkende
Stoffe (z. B. Glucocorticoide und deren Derivate wie Triamcinolonacetonid; Bufexamac, Kamil
lenextrakt, Hamamelisextrakt, Gerbstoffe, Bisabolol, Ammoniumbituminosulfonat, Acetylsalicyl
säure, Atlantoin), Immunsuppressiva (z. B. Methotrexat, Ciclosporin, Retinoide (z. B. lsotretinoin,
Acitretinoin, Tazaroten)), Antünfektiva (z. B. Clindamycin, Tetracycline), Cytokine (z. B.
Interleukine, lnterferone, Tumornekrosefaktoren), Antiseptika (z. B. Chlorhexidin, Benzalkonium
chlorid, 8-Hydroxychinoline, Ethacridin, Hexetidin, Acriflaviniumchlorid, Benzoxoniumchlorid,
Bibrocathol, Dequaliniumsalze, Ethanol, 2-Propanol, 1-Propanol, Azelainsäure, Resorcin,
Triclosan, Farnesol, Diglycerinmonocaprinat, kolloidales Silber, Süberchforid, Gentamycin,
Salicylsäure, ozonisiertes Olivenöl, Benzoylperoxid), Virustatika (z. B. Aciclovir, Penciclovir,
Foscarnet-Natrium, Idoxuridin, Trifluridin, Tromantadin, Vidarabin), Adstringentien (z. B. Tannin,
Eichenrindeextrakt, Wismutgallat), Extrakte mit spezifischen Wirkungen (z. B. Aloe-Vera-Extrakt,
Grüner Tee-Extrakt, Algenextrakt, Echinaceaextrakt, Arnikaextrakt, Gurkenextrakt, Hopfenextrakt,
Karottenextrakt, Kleieextrakt, Hamamelisextrakt, Hefeextrakt, Gingko biloba-Extrakt), Pflanzenöle
mit spezifischen Wirkungen (z. B. Rosmarinöl, Kamillenöl, Salbeiöl, Calendulaöl, Lavendelöl,
Johanniskrautöl, Melissenöl, Sanddornöl, Teebaumöl, Zedernholzöl, Zypressenöl), Öle mit einem
hohen Gehalt an veresterten hochungesättigten (essentiellen) Fettsäuren (z. B. Nachtkerzenöl,
Johannisbeerkernöl, Borretschöl, Hagebuttenöl, Sojaöl, Fischöl) sowie barrierestabilisierende
Säuren (z. B. Linolsäure, 12-Hydroxystearinsäure, Stearinsäure, Isostearinsäure, Palmitinsäure,
11-Hydroxypalmitinsäure, Proteinhydrolysatkondensate ("Lipacide", z. B. Palmitoyiweizen
proteinhydrolysat, Dipalmitoylhydroxyprolin, N-Palmitoylglutaminsäure), Hyaluronsäure) und
Einzelstoffe mit speziellen Wirkungen (z. B. 1,2-Dithiacyclopentan-3-valeriansäre, Adapalen,
Ammoidin, Tioxolon, Minoxidil, Fluorouracil) sein. Darüber hinaus gehören zu den Wirkstoffen
Substanzen, die in der Lage sind, Schwermetallkationen am Eindringen in die Haut zu hindern (z. B. EDTA, 1-Hydroxyethan-1,1-diphosphonsäure, Trimethylammonioacetat, CM-Glucan, Chitosan,
Polyvinylalkohol, Polyvinylpyrrolidon, Bentonite, Kaolin, Cyclodextrine, Pectine und deren
Derivate, Alginsäure und Alginate, Polysaccharide und deren Derivate (z. B. mikrokristalline
Cellulose, Celluloseether, Methylcellulose, Hydroxypropylcellulose, Hydroxypropylmethylcellulose,
Carmellose, Carboxymethylcellulose, Tragant, Tragacanthin), Carraghenane, Xanthan,
Johannisbrotkernmehl, Guarkernmehl und dessen Derivate, Arabisches Gummi, Polyacrylate und
deren Copolymerisate). Zu den Wirkstoffen zählen sinngemäß auch abdeckende Stoffe und
Pigmente wie z. B. Magnesiumoxid, Magnesiumcarbonat, Magnesiumaluminiumsilikat, Mag
nesiumstearat, Magnesiumisostearat, Talkum, Calciumcarbonat, Zinkoxid, Zinkcarbonat,
Zinkstearat, Zinklaurat, Titandioxid, Eisenoxid, Eisenhexacyanoferrat, Wismutoxychlorid,
Aluminiumoxid, Alumosilikate, Siliciumdioxid, Aerosil, Bornitrid, Glimmer und Gesteinsmehle.
Pigmente, die gegebenenfalls mit bekannten verträglichen Farbstotfen oder Bräunungsmitteln, wie
z. B. Dihydroxyaceton, abgemischt sein können, haben in den erfindungsgemäßen Hautschutz
präparaten den Sinn, einerseits vor äußerlichen Schadstoffen zu schützen, andererseits örtlich
begrenzte Hautschäden oder Hautanomalien zu überdecken, um die Haut vor entsprechenden,
psychisch bedingten Reaktionen zu schützen (Kratzen, Drücken etc.). Alle Wirkstoffe können
allein oder in einer entsprechend sinnvollen Kombination in den erfindungsgemäßen Haut
schutzpräparaten enthalten sein. Sofern eine Einstellung des pH's aufgrund sauer reagierender
Wirkstoffe notwendig ist, kann dies mittels indifferenter Basen wie z. B. Natriumhydroxid,
Kaliumhydroxid, Trometamol, Arginin oder Lysin erfolgen.
Besonders bevorzugt sind die Mono-, Di- und Triglyceride der Rizinolsäure, der 12-Hydroxystea rinsäure und der Linolsäure, Linolsäureethylester, Palmitinsäure, Stearinsäure, Sheabutter, Bie nenwachs, Jojobaöl, Squalan, Cholesterin, Vitamine der A, C, E und D-Reihe sowie deren Acetate, Palmitate, Stearate und Linolate, Panthenol, Biotin, Allantoin, Lidocain, Salicylsäure, Azelainsäure, Ethanol, Avocadoöl, Nachtkerzenöl, Johannisbeerkernöl, Hagebuttenöl, Fischöl, ozonisiertes Olivenöl, Magnesiumaluminiumsilikat, Eisenoxid, Zinkoxid, Titandioxid, Kaolin, Gesteinsmehl, Polyacrylate und deren Copolymerisate, Xanthan, Hamamelisextrakt, Aloe-Vera- Extrakt und deren Mischungen untereinander.5. Dermatological and cosmetic active ingredients of the skin protection preparations according to the invention are skin-protecting lipids and waxes such as, for. B. mono-, di-, tri- and polyglycerides of ricinoleic, 12-hydroxystearic and 11-hydroxypalmitic acid, castor oil, hydrogenated castor oil, octyl dodecyl ester of ricinoleic acid, octyl 12-hydroxystearic acid, beeswax, Japanese wax, carnauba wax, cetyl palmitate, cocoa butter, cocoa butter, cocoa butter , Squalene, squalane, cholesterol, cholesteryl sulphate, phytosterols, lanolin, lanolin alcohols and their derivatives, ceramides, sphingolipids, sphinganine, sphingosine, sphingosine 1-phosphate, sphingomyelin, C 12 -C 15 alkyl benzoate, linoleic acid methyl and ethyl ester Linoleic acid mono-, di- and triglycerides, isopropyl myristate, isopropyl palmitate and natural fatty oils, such as. B. avocado oil, wheat germ oil, macadamia nut oil, apricot kernel oil, almond oil, hemp oil, linseed oil, sesame oil, olive oil, sunflower oil, peanut oil in natural and hydrogenated form. Other active ingredients can include vitamins and provitamins (in particular A, B complex, C, E, D and their usual derivatives such as vitamin A acid, vitamin A acetate, vitamin A palmitate, vitamin C palmitate, vitamin E acetate, - palmitate and linoleate, alfacalcidol, calcitriol, colecalciferol, ergocalciferol, transcalcifediol, calciprotriol, calcifediol, vitamin D 3 , β-carotene, panthenol, pantothenic acid, biotin), itch-relieving surface anesthetics (e.g. 20%, lidocaine, benzocaine, lidocaine, aqueous urea solutions, isoprenaline, crotamiton, quinisocaine), itch-relieving H 1 antihistamines (e.g. meclozin, cetirizine, promethazine, diphenhydramine, chlophenoxamine, doxylamine, pheniramine, bromphenira min. Oxatomide, terfenadine, astemizole), antifungals (e.g. econazole, bifonazole, isoconazole, oxiconazole, tioconazole, fenticonazole, clotrimazole, miconazole, ketoconazole, itraconazole, flucanazole, sertaconafinol, terbaconazole, t Naftifin, omoconazole, tolnaftat, amorolfin, amphotericin B, nystatin, natamycin, griseofulvin, flucytosine, ciclopirox, tolciclate, undecylenic acid), substances with an anti-inflammatory effect (e.g. B. glucocorticoids and their derivatives such as triamcinolone acetonide; Bufexamac, chamomile extract, witch hazel extract, tannins, bisabolol, ammonium bituminosulfonate, acetylsalicylic acid, atlantoin), immunosuppressants (e.g. methotrexate, ciclosporin, retinoids (e.g. isotretinoin, acitretinoin, antioxidant) (tazarotenin) , Tetracyclines), cytokines (e.g. interleukins, interferons, tumor necrosis factors), antiseptics (e.g. chlorhexidine, benzalkonium chloride, 8-hydroxyquinolines, ethacridine, hexetidine, acriflavinium chloride, benzoxonium chloride, bibrocathole, dequalinium salts, ethanol, ethanol 1-propanol, azelaic acid, resorcinol, triclosan, farnesol, diglycerol monocaprinate, colloidal silver, süberchforid, gentamycin, salicylic acid, ozonized olive oil, benzoyl peroxide), antivirals (e.g. aciclovir, penciclovir, foscarnet trom, sodium, idlurididine, idoxuridine, idoxuridine) ), Astringents (e.g. tannin, oak bark extract, bismuth gallate), extracts with specific effects (e.g. aloe vera extract, green tea extract, algae extract, ech inacea extract, arnica extract, cucumber extract, hop extract, carrot extract, bran extract, witch hazel extract, yeast extract, gingko biloba extract), vegetable oils with specific effects (e.g. B. rosemary oil, chamomile oil, sage oil, calendula oil, lavender oil, St. John's wort oil, lemon balm oil, sea buckthorn oil, tea tree oil, cedarwood oil, cypress oil), oils with a high content of esterified highly unsaturated (essential) fatty acids (e.g. evening primrose oil, currant oil, rosehip oil, borage oil) Soybean oil, fish oil) as well as barrier-stabilizing acids (e.g. linoleic acid, 12-hydroxystearic acid, stearic acid, isostearic acid, palmitic acid, 11-hydroxypalmitic acid, protein hydrolyzate condensates ("lipacides", e.g. palmitoy wheat protein hydrolyzate, dipalmitoylhydroxy acidoloyluralurallurallurolallurolurolallurolurolurallalurallurolallurol), nologlylaluronic acid, and single substances with special effects (e.g. 1,2-dithiacyclopentane-3-valerian acid, adapalene, ammoidin, tioxolone, minoxidil, fluorouracil). In addition, the active ingredients include substances that are able to prevent heavy metal cations from penetrating the skin (e.g. EDTA, 1-hydroxyethane-1,1-diphosphonic acid, trimethylammonioacetate, CM-glucan, chitosan, polyvinyl alcohol, polyvinylpyrrolidone , Bentonites, kaolin, cyclodextrins, pectins and their derivatives, alginic acid and alginates, polysaccharides and their derivatives (e.g. microcrystalline cellulose, cellulose ethers, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, carmellose, carboxymethyl cellulose, tragacanth, tragacanthine kernel, nutmeg, xanthine, xanthan gum, carraghenane, xanthan gum, xanthan gum, xanthan gum, carraghenane xanthine , Guar gum and its derivatives, arabic gum, polyacrylates and their copolymers). The active ingredients also include covering substances and pigments such as. As magnesium oxide, magnesium carbonate, magnesium aluminum silicate, magnesium stearate, magnesium isostearate, talc, calcium carbonate, zinc oxide, zinc carbonate, zinc stearate, zinc laurate, titanium dioxide, iron oxide, iron hexacyanoferrate, bismuth oxychloride, aluminum oxide, aluminum silicates, silicon dioxide, aerosil, boron nitride, mica. Pigments, optionally with known compatible dyes or tanning agents, such as. B. dihydroxyacetone, can be mixed, have the sense in the skin protection preparations according to the invention on the one hand to protect against external pollutants, on the other hand to cover localized skin damage or skin anomalies in order to protect the skin from corresponding psychological reactions (scratching, pressing, etc. ). All active ingredients can be contained alone or in a correspondingly meaningful combination in the skin protection preparations according to the invention. If an adjustment of the pH is necessary due to acidic active ingredients, this can be done using indifferent bases such as. B. sodium hydroxide, potassium hydroxide, trometamol, arginine or lysine.
The mono-, di- and triglycerides of ricinoleic acid, 12-hydroxystearic acid and linoleic acid, ethyl linoleate, palmitic acid, stearic acid, shea butter, beeswax, jojoba oil, squalane, cholesterol, vitamins A, C, E and D- are particularly preferred. Series and their acetates, palmitates, stearates and linolates, panthenol, biotin, allantoin, lidocaine, salicylic acid, azelaic acid, ethanol, avocado oil, evening primrose oil, currant seed oil, rose hip oil, fish oil, ozonized olive oil, magnesium aluminum silicate, iron oxide, zinc oxide, titanium dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaolin dioxide, kaamin dioxide, ka Polyacrylates and their copolymers, xanthan, witch hazel extract, aloe vera extract and their mixtures with one another.
Ein wesentliches Charakteristikum der erfindungsgemäßen Hautschutzpräparate ist, daß sie alternativ entweder aus hydriertem (gesättigtem) Phosphatidylcholin, mittelkettigen Triglyceriden, Salzen, Feuchthaltesubstanzen und Wirkstoffen hergestellt werden oder die Wirkstoffe oder Wirkstoffgemische ganz oder teilweise erst später vom Fachpersonal in bereits fertige Präparate, die aus den übrigen Bestandteilen bestehen, vor Ort eingearbeitet werden. Unter Fachpersonal sind z. B. Apotheker, Dermatologen, Kosmetikerinnen und einschlägig ausgebildetes Laborpersonal zu verstehen.An essential characteristic of the skin protection preparations according to the invention is that they are alternative either from hydrogenated (saturated) phosphatidylcholine, medium-chain triglycerides, salts, Humectants and active ingredients are produced or the active ingredients or active ingredient mixtures in whole or in part only later by the specialist staff in already finished preparations, which from the rest Components exist, are incorporated on site. Among specialist staff are e.g. B. pharmacist, To understand dermatologists, beauticians and relevant laboratory staff.
Die erfindungsgemäßen Hautschutzpräparate dienen neben dem Schutz vor exogen oder endogen bedingten Barrierestörungen und Hautschäden vor allem dem Schutz der Haut vor wässerigen und öligen, äußerlich einwirkenden Stoffen oder deren Gemischen sowie je nach Hautbeschaffenheit auch dem Schutz vor Beanspruchungen durch trockene und besonders feuchte klimatische Bedingungen. Daher können die Hautschutzpräparate in Innenraumbereichen und im Freien genutzt werden. Da ein vorrangiges Ziel der Schutz von stark beanspruchter, sensibler und zu Hautkrankheiten disponierter Haut ist, sind die erfindungsgemäßen Hautschutzpräparate für einen 24-Stunden-Schutz konzipiert. Damit ist gemeint, daß entsprechende Anwendungen der Hautschutzpräparate sowohl im gewerb lichen als auch im privaten Bereich, d. h. in Freizeit, Urlaub und Haushalt, stattfinden sollen, um die Haut jederzeit präventiv zu schützen und die Eigenregeneration zu fördern. Die Anwendung ist nicht auf bestimmte Hautareale wie Hände und Gesicht beschränkt, sondern kann sich auch auf den gesamten Körper oder spezielle andere Hautbereiche erstrecken. Die erfindungsgemäßen Haut schutzpräparate sind so eingestellt, daß sie sich gut verteilen lassen und in der Regel schnell einziehen. Sie lassen sich z. B. vorteilhaft bei Tätigkeiten anwenden, bei denen die Haut besonders lange durch Wasser beansprucht wird, wie z. B. beim Wassersport und im Haushalt. Ein interessanter Anwendungsbereich ist auch der Hautschutz bei Inkontinenz und Windelträgern. Bei längerem Kontakt mit Wasser erweist sich das oben beschriebene, vergleichsweise geringe Quellvermögen der Haut nach der Applikation der Hautschutzmittel als großer Vorteil.The skin protection preparations according to the invention serve, in addition to protection against exogenous or endogenous related barrier disorders and skin damage especially protecting the skin from watery and oily, externally acting substances or their mixtures as well as depending on the nature of the skin protection against stress caused by dry and particularly humid climatic conditions. Therefore, the skin protection preparations can be used indoors and outdoors. There a The primary goal is the protection of heavily used, sensitive and predisposed to skin diseases The skin protection preparations according to the invention are designed for 24-hour protection. This means that appropriate applications of the skin protection preparations both in the commercial liche as well as in the private sector, d. H. in leisure, vacation and household, should take place to the Protect skin at all times and promote self-regeneration. The application is not limited to certain areas of the skin such as hands and face, but can also affect the skin entire body or special other skin areas. The skin according to the invention Protective preparations are adjusted so that they can be distributed well and are usually quick move in. You can z. B. advantageous for activities in which the skin is particularly is used for a long time by water, such as. B. in water sports and in the household. An interesting one The area of application is also skin protection for incontinence and diaper wearers. For a long time Contact with water proves the comparatively low swelling capacity described above Skin after the application of the skin protection agents as a great advantage.
Exemplarisch lassen sich die erfindungsgemäßen Hautschutzpräparate gegen die folgenden Stoffklassen anwenden, wobei die Zusammensetzung im Einzelfall auf besondere Eigenschaften dieser Stoffe eingestellt werden kann: Wassergemischte Kühlschmierstoffe, wässerige Arbeitsstoffe und Wasser, wässerige Spüllösungen, Metallsalze, Metallstäube, Futtermittel- und Getreidestäube, Mehlstäube, Holzstaub, Konservierungsmittel, Desinfektionsmittel, Dauerwellmittel, Haarfarben, Duftstoffe, Fleisch, Fisch, Körperexkrete (Kot, Urin), Körpersekrete (Schweiß, Speichel, Schleim), Gemüse, Pflanzenzwiebeln, Pflanzensäfte, Obst, Enzyme, Imprägniermittel, oberflächenaktive Verbindungen, Photochemikalien, nichtwassermischbare Kühlschmierstoffe, technische Öle, Pflanzenöle, Fette, Wachse, Teere, Harze, Farben und Farbstoffe, Fußbodenpflegemittel, Gummihandschuhe, Latex, Vulkanisationsmittel, Kleber, Dentalchemikalien.The skin protection preparations according to the invention can be used as examples against the following Apply substance classes, whereby the composition in individual cases has special properties these substances can be adjusted: water-mixed cooling lubricants, aqueous working materials and water, aqueous rinsing solutions, metal salts, metal dusts, feed and grain dusts, Flour dusts, wood dust, preservatives, disinfectants, permanent waving agents, hair colors, Fragrances, meat, fish, body excrement (faeces, urine), body secretions (sweat, saliva, mucus), Vegetables, bulbs, plant juices, fruits, enzymes, impregnants, surface-active Compounds, photochemicals, water-immiscible cooling lubricants, technical oils, Vegetable oils, fats, waxes, tars, resins, paints and dyes, floor care products, Rubber gloves, latex, vulcanizing agents, glue, dental chemicals.
Es versteht sich von selbst, daß die erfindungsgemäßen Hautschutzpräparate je nach Hautbeschaffenheit auch bei besonders hoher und niedriger Luftfeuchtigkeit, bei Dämpfen und Aerosolen oder als Kältesalben angewandt werden können.It goes without saying that the skin protection preparations according to the invention depend on Skin texture even with particularly high and low humidity, with vapors and Aerosols or as cold ointments can be used.
Die Gehalte der Hauptkomponenten der erfindungsgemäßen Hautschutzpräparate können in den
folgenden Grenzen variieren:
The contents of the main components of the skin protection preparations according to the invention can vary within the following limits:
- 1. Phosphatidylcholin (gesättigt) 0,10-10,00 Gew.-%,1. phosphatidylcholine (saturated) 0.10-10.00% by weight,
- 2. mittelkettige Triglyceride 1,00-50,00 Gew.-%,2. medium-chain triglycerides 1.00-50.00% by weight,
- 3. Salze 0,01-10,00 Gew.-%,3. salts 0.01-10.00% by weight,
- 4. Feuchthaltesubstanzen 1,00-20,00 Gew.-%,4. moisturizing substances 1.00-20.00% by weight,
- 5. dermatologische oder kosmetische Wirkstoffe 0,01-20,00 Gew.-%,5. dermatological or cosmetic active substances 0.01-20.00% by weight,
- 6. Wasser 20,00-95,00 Gew.-%.6. Water 20.00-95.00% by weight.
Vorzugsweise betragen die Gehalte der Hauptkomponenten der erfindungsgemäßen Hautschutz
präparate:
The contents of the main components of the skin protection preparations according to the invention are preferably:
- 1. Phosphatidylcholin (gesättigt) 0,50-6,00 Gew.-%,1. phosphatidylcholine (saturated) 0.50-6.00% by weight,
- 2. mittelkettige Triglyceride 5,00-40,00 Gew.-%,2. medium-chain triglycerides 5.00-40.00% by weight,
- 3. Salze 0,10-5,00 Gew.-%,3. salts 0.10-5.00% by weight,
- 4. Feuchthaltesubstanzen 1,00-20,00 Gew.-%,4. moisturizing substances 1.00-20.00% by weight,
- 5. dermatologische oder kosmetische Wirkstoffe 1,0-10,00 Gew.-%,5. dermatological or cosmetic active ingredients 1.0-10.00% by weight,
- 6. Wasser 30,00-85,00 Gew.-%.6. Water 30.00-85.00 wt%.
Je nach Zusammensetzung haben die erfindungsgemäßen Hautschutzpräparate eine salbenartige, cremige oder milchige Konsistenz. Die Zusammensetzung und Herstellung der erfindungsgemäßen Hautschutzpräparate und ihre Anwendung bei Nutzung unterschiedlicher Komponenten wird in den folgenden Beispielen illustriert. Die den Komponenten vorgestellten Zahlen von 1)-6) entsprechen der in der Beschreibung angegebenen Klassifizierung der Hauptkomponenten der erfindungsgemäßen Hautschutzpräparate: 1) hydriertes (gesättigtes) Phosphatidylcholin, 2) mittelkettige Triglyceride, 3) Salze, 4) Feuchthaltesubstanzen, 5) dermatologische und kosmetische Wirkstoffe, 6) Wasser. In den nachstehenden Beispielen wird als hydriertes (gesättigtes) Phosphatidylchoün das käufliche Phospholipon 90 H der Fa. Nattermann Phospholipid GmbH, Köln, mit einem Phosphatidylcholin gehalt von ca. 95% eingesetzt; das Phosphatidylcholin stammt aus der Sojabohne. Der in den Beispielen angegebenen Gehalte der Komponente 1) ist sinngemäß an den jeweiligen Phosphat idylcholingehalt anzupassen, d. h. bei geringeren Phosphatidylcholingehalten wird eine entsprechend höhere Menge der Komponente 1) und entsprechend weniger 6) Wasser kalkuliert. Bei höheren Phosphatidylcholingehalten wird umgekehrt die Mengen an 1) reduziert und entsprechend mehr 6) Wasser kalkuliert. Da sich bei einem Ersatz von z. B. Phospholipon 90 H durch Phospholipon 80 H oder anderen verfügbaren Qualitäten die Konsistenzen der Produkte erheblich verändern können, kann gegebenenfalls auch ein 1 : 1-Austausch oder ein Austausch mit anderem Verhältnis vorgenommen werden, um mehr salbenartige, cremige oder milchige Konsistenzen zu erreichen.Depending on the composition, the skin protection preparations according to the invention have an ointment-like, creamy or milky consistency. The composition and manufacture of the invention Skin protection products and their use when using different components is in the following examples. The numbers from 1) -6) presented to the components correspond to in the description of the classification of the main components of the invention Skin protection products: 1) hydrogenated (saturated) phosphatidylcholine, 2) medium-chain triglycerides, 3) Salts, 4) humectants, 5) dermatological and cosmetic active ingredients, 6) water. In the The following examples are available as hydrogenated (saturated) phosphatidyl chlorine Phospholipon 90 H from Nattermann Phospholipid GmbH, Cologne, with a phosphatidylcholine content of approx. 95% used; the phosphatidylcholine comes from the soybean. The one in the Contents of component 1) given in the examples are analogous to the respective phosphate adjust idylcholine content, d. H. with lower phosphatidylcholine contents, one is used accordingly higher amount of component 1) and correspondingly less 6) water calculated. At higher Conversely, phosphatidylcholine content reduces the amounts of 1) and accordingly more 6) Water calculated. Since a replacement of z. B. Phospholipon 90 H by Phospholipon 80 H or other available qualities can significantly change the consistency of the products, may also be a 1: 1 exchange or an exchange with a different ratio be made to achieve more ointment-like, creamy or milky consistencies.
Die Komponenten 1) bis 5) werden in einem dem Fachmann geläufigen Verfahren gemischt, auf eine Temperatur von 50-80°C erwärmt und in der Wasserphase 6), die auf die gleiche Temperatur gebracht wird, dispergiert, mit einem Leitstrahlmischer, Rotorstatorgerät oder Hochdruck homogenisator homogenisiert, abgekühlt und nochmals homogenisiert. Je nach Einsatzzweck bzw. Konsistenz des gewünschten Hautschutzpräparates werden der Dispergiervorgang und die Homogenisationsschritte über längere oder kürzere Zeit durchgeführt. Es ergeben sich daraus - wie ebenfalls dem Fachmann bekannt ist - festere oder flüssigere Produkte.Components 1) to 5) are mixed in a process familiar to the person skilled in the art Temperature of 50-80 ° C warmed and in the water phase 6), the same temperature brought, dispersed, with a jet mixer, rotor stator or high pressure homogenizer homogenized, cooled and homogenized again. Depending on the application or The dispersion process and the consistency of the desired skin protection preparation Homogenization steps carried out over a longer or shorter time. It follows - how is also known to those skilled in the art - firmer or more liquid products.
Bei Gel- oder Filmbildnern oder generell wasserlöslichen Einsatzstoffen aus den Gruppen 3) Salze, 4) Feuchthaltesubstanzen und 5) dermatologische oder kosmetische Wirkstoffe kann es sinnvoll sein, diese in der Wasserphase 6) zu lösen und dann die Dispergier- und Homogenisierschritte folgen zu lassen. For gel or film formers or generally water-soluble feedstocks from groups 3) salts, 4) Moisturizing substances and 5) dermatological or cosmetic active ingredients, it may be useful to solve this in the water phase 6) and then the dispersing and homogenizing steps follow to let.
Die dermatologischen oder kosmetischen Wirkstoffe 5) lassen sich auch nachträglich in entsprechende Basiscremes, die aus 1), 2), 3), 4) und 6) nach den gleichen beschriebenen Verfahren und Beispielen hergestellt werden, bei einer Temperatur von 15 bis 30°C einrühren. Nach entsprechender Homogenisierung entstehen ebenfalls die erfindungsgemäßen Hautschutzpräparate. Dabei kann es auch sinnvoll sein, die Basiscremes bereits mit einem Teil der dermatologischen oder kosmetischen Wirkstoffe 5) zu versehen.The dermatological or cosmetic active ingredients 5) can also be added subsequently corresponding base creams made from 1), 2), 3), 4) and 6) according to the same procedures described and examples are prepared, stir at a temperature of 15 to 30 ° C. To Appropriate homogenization also produces the skin protection preparations according to the invention. It may also be useful to already use some of the dermatological or base creams cosmetic active ingredients 5).
So kann z. B. die Basiscreme für Hautschutzpräparate bei Disposition zu trockener Haut (vgl. Beispiel
20) aus:
So z. B. the basic cream for skin protection products when disposing of dry skin (see Example 20):
hergestellt werden und die Komponente 5) Avocadoöl (9,5%) zu einem späteren Zeitpunkt eingerührt werden. Alternativ zum Avocadoöl können aber z. B. auch Jojobaöl, Nachtkerzenöl, Weizenkeimöl, Macadamianußöl oder z. B. Cetylpalmitat, gelöst in Isopropylmyristat, und andere sinnvolle Kombinationen in gleicher Menge hinzugefügt werden. Selbstverständlich können statt einem Öl z. B. auch ein Extrakt oder ein wasserlöslicher Wirkstoff oder entsprechende Stoffgemische aus dermato logischen oder kosmetischen Wirkstoffen in die Basiscremes eingerührt werden.be prepared and component 5) avocado oil (9.5%) stirred at a later date will. As an alternative to avocado oil, e.g. B. also jojoba oil, evening primrose oil, wheat germ oil, Macadamia nut oil or e.g. B. cetyl palmitate, dissolved in isopropyl myristate, and other useful Combinations can be added in the same amount. Of course, instead of an oil such. B. also an extract or a water-soluble active ingredient or corresponding mixtures of substances from dermato logical or cosmetic active ingredients are stirred into the base creams.
Claims (5)
- 1. Phosphatidylcholin (gesättigt) 0,10-10,00 Gew.-%,
- 2. mittelkettige Triglyceride 1,00-50,00 Gew.-%,
- 3. Salze 0,01-10,00 Gew.-%,
- 4. Feuchthaltesubstanzen 1,00-20,00 Gew.-%,
- 5. dermatologische oder kosmetische Wirkstoffe 0,01-20,00 Gew.-% und
- 6. Wasser 20,00-95,00 Gew.-% enthält.
- 1. phosphatidylcholine (saturated) 0.10-10.00% by weight,
- 2. medium-chain triglycerides 1.00-50.00% by weight,
- 3. salts 0.01-10.00% by weight,
- 4. moisturizing substances 1.00-20.00% by weight,
- 5. dermatological or cosmetic active ingredients 0.01-20.00 wt .-% and
- 6. Water contains 20.00-95.00% by weight.
- 1. Phosphatidylcholin (gesättigt) 0,50-6,00 Gew.-%,
- 2. mittelkettige Triglyceride 5,00-40,00 Gew.-%,
- 3. Salze 0,10-5,00 Gew.-%,
- 4. Feuchthaltesubstanzen 1,00-20,00 Gew.-%,
- 5. dermatologische oder kosmetische Wirkstoffe 1,0-10,00 Gew.-%,
- 6. Wasser 30,00-85,00 Gew.-% enthält.
- 1. phosphatidylcholine (saturated) 0.50-6.00% by weight,
- 2. medium-chain triglycerides 5.00-40.00% by weight,
- 3. salts 0.10-5.00% by weight,
- 4. moisturizing substances 1.00-20.00% by weight,
- 5. dermatological or cosmetic active ingredients 1.0-10.00% by weight,
- 6. Water contains 30.00-85.00% by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1998157492 DE19857492A1 (en) | 1998-12-14 | 1998-12-14 | Cosmetic or dermatological skin-protective compositions, containing saturated phosphatidyl choline to give good barrier stabilizing and active agent penetrating effects |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1998157492 DE19857492A1 (en) | 1998-12-14 | 1998-12-14 | Cosmetic or dermatological skin-protective compositions, containing saturated phosphatidyl choline to give good barrier stabilizing and active agent penetrating effects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE19857492A1 true DE19857492A1 (en) | 2000-06-15 |
Family
ID=7890947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1998157492 Withdrawn DE19857492A1 (en) | 1998-12-14 | 1998-12-14 | Cosmetic or dermatological skin-protective compositions, containing saturated phosphatidyl choline to give good barrier stabilizing and active agent penetrating effects |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE19857492A1 (en) |
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10123771A1 (en) * | 2001-05-16 | 2002-11-21 | Beiersdorf Ag | Use of electrolytes in compositions for the treatment or prevention of dry skin |
| DE10124475A1 (en) * | 2001-05-19 | 2002-11-21 | Beiersdorf Ag | Cosmetic or dermatological composition containing ketohexose, useful for treating e.g. inflammation, pigment disorders, and skin aging, promotes barrier function |
| DE10133201A1 (en) * | 2001-07-07 | 2003-01-23 | Beiersdorf Ag | Use of topical compositions containing electrolytes in combination with polyols and/or urea to, e.g. improve skin condition or to treat or prevent skin disorders |
| DE10133199A1 (en) * | 2001-07-07 | 2003-01-23 | Beiersdorf Ag | Use of topical compositions containing cineol and its derivatives and natural products containing them e.g. to improve skin condition and to treat or prevent skin disorders |
| WO2003035021A1 (en) * | 2001-10-21 | 2003-05-01 | Jan Faergemann | Potentiated topical composition |
| EP1293204A4 (en) * | 2000-04-26 | 2004-01-21 | Kowa Co | PREPARATION OF A UREA-BASED GEL |
| EP1449515A1 (en) * | 2003-02-21 | 2004-08-25 | Cognis Deutschland GmbH & Co. KG | Anti-acne agents |
| WO2005034967A1 (en) * | 2003-10-10 | 2005-04-21 | Hans-Joachim Lach | Pharmaceutical or cosmetic compositions for treating skin |
| DE102004013607A1 (en) * | 2004-03-18 | 2005-10-06 | Beiersdorf Ag | Lipid combination against ash-colored skin |
| EP1609460A1 (en) * | 2004-06-24 | 2005-12-28 | The Procter & Gamble Company | Skin care compositions comprising fatty material having a melting temperature range of 21-40 C |
| WO2006103056A3 (en) * | 2005-03-30 | 2006-11-23 | Gerhard Sauermann | Topical product containing betaine for preventing and treating nappy rash |
| DE102005051889A1 (en) * | 2005-10-29 | 2007-05-03 | Apotheker Walter Bouhon Gmbh | Cosmetic or dermatological preparation for protection against photoaging |
| JP2008508215A (en) * | 2004-07-30 | 2008-03-21 | マイコス イタリアーナ ディ コミーニ ミロ アンド チ. エッセ.ア.エッセ | N-acylated derivatives of dicarboxylic acids in amino acid and plant protein hydrolysates and their use in cosmetics and medicine |
| DE102006045389A1 (en) * | 2006-09-26 | 2008-03-27 | Maxim Markenprodukte Gmbh & Co. Kg | Topically acting dermatological humectant comprises hyaluronic acid and panthenol in the multilamellar layers of hydrogenated liposomes |
| JP2008291014A (en) * | 2007-04-27 | 2008-12-04 | Fancl Corp | Milky liquid cosmetics |
| JP2010043027A (en) * | 2008-08-13 | 2010-02-25 | Kracie Home Products Ltd | Oil-in-water type emulsified cosmetic |
| DE102009008940A1 (en) | 2009-02-13 | 2010-08-19 | Rolf Ludl | Combination, useful for the cosmetic and/or medical treatment, and for producing a cosmetic product or a drug, comprises a hyaluronic acid gel and a cream in separate preparations |
| US20120122936A1 (en) * | 2010-11-11 | 2012-05-17 | Conopco, Inc., D/B/A Unilever | Leave-on nonsolid skin conditioning compositions containing 12-[(12-hydroxyoctadecanoyl)oxy] octadecanoic acid |
| DE102011110749A1 (en) | 2011-08-16 | 2013-02-21 | Gabriele Blume | Cosmetic or pharmaceutical composition with lamellar structures using sucrose fatty triesters - simple and easy preparation |
| WO2012152568A3 (en) * | 2011-05-12 | 2013-09-26 | Unilever N.V. | A skin lightening composition |
| DE102012023927A1 (en) * | 2012-12-06 | 2014-06-12 | Heinrich Huber | Ointment useful for treating psoriasis without side effects, comprises natural materials, extracts of salt pork, white beeswax and lavender oil, and does not contain preservatives |
| WO2017063748A1 (en) | 2015-10-16 | 2017-04-20 | Bernd Kuhs | Composition and method for producing dermatological and cosmetic preparations having pronounced lamellar structures using phosphatidycholine and fermentation by microorganisms |
| WO2018069814A1 (en) | 2016-10-11 | 2018-04-19 | MAUSER, Johannes, Alois | Method for producing dermatological and cosmetic preparations |
| EP3421096A1 (en) * | 2017-06-30 | 2019-01-02 | Athenion AG | Method for solubilizing poorly water-soluble cosmetic agents |
| WO2019086195A1 (en) | 2017-11-06 | 2019-05-09 | Cosmetolab Ag | Process for preparing topical formulations by means of ultrasound and formulations so obtained |
| CN111587243A (en) * | 2018-01-11 | 2020-08-25 | 麦翠奥制药公司 | Method for solubilizing 5-amino-2, 3-dihydro-1, 4-phthalazinedione |
| DE102005008299B4 (en) | 2005-02-23 | 2025-07-10 | Bio-Gate Ag | Cosmetic and/or dermatological formulation, process for its preparation and use of the formulation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4021082A1 (en) * | 1990-07-03 | 1992-01-23 | Hans Dr Lautenschlaeger | Skin care product with high lipid content - contains a bi:layer source, salts of organic acids, alcohol, stabiliser and lipid(s) |
-
1998
- 1998-12-14 DE DE1998157492 patent/DE19857492A1/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4021082A1 (en) * | 1990-07-03 | 1992-01-23 | Hans Dr Lautenschlaeger | Skin care product with high lipid content - contains a bi:layer source, salts of organic acids, alcohol, stabiliser and lipid(s) |
Cited By (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1293204A4 (en) * | 2000-04-26 | 2004-01-21 | Kowa Co | PREPARATION OF A UREA-BASED GEL |
| DE10123771A1 (en) * | 2001-05-16 | 2002-11-21 | Beiersdorf Ag | Use of electrolytes in compositions for the treatment or prevention of dry skin |
| DE10123771B4 (en) * | 2001-05-16 | 2019-01-10 | Beiersdorf Ag | Use of electrolytes to strengthen the barrier function of the skin |
| DE10124475A1 (en) * | 2001-05-19 | 2002-11-21 | Beiersdorf Ag | Cosmetic or dermatological composition containing ketohexose, useful for treating e.g. inflammation, pigment disorders, and skin aging, promotes barrier function |
| DE10133201A1 (en) * | 2001-07-07 | 2003-01-23 | Beiersdorf Ag | Use of topical compositions containing electrolytes in combination with polyols and/or urea to, e.g. improve skin condition or to treat or prevent skin disorders |
| DE10133199A1 (en) * | 2001-07-07 | 2003-01-23 | Beiersdorf Ag | Use of topical compositions containing cineol and its derivatives and natural products containing them e.g. to improve skin condition and to treat or prevent skin disorders |
| WO2003007892A3 (en) * | 2001-07-07 | 2003-12-11 | Beiersdorf Ag | Cosmetic and dermatological preparations containing electrolyte, for the treatment and active prevention of dry skin and other negative changes in the physiological homeostasis of the skin |
| AU2002339819B2 (en) * | 2001-10-21 | 2007-03-15 | Ambria Dermatology Ab | Potentiated topical composition |
| US8642053B2 (en) | 2001-10-21 | 2014-02-04 | Ambria Dermatology Ab | Potentiated topical composition |
| WO2003035021A1 (en) * | 2001-10-21 | 2003-05-01 | Jan Faergemann | Potentiated topical composition |
| EP1449515A1 (en) * | 2003-02-21 | 2004-08-25 | Cognis Deutschland GmbH & Co. KG | Anti-acne agents |
| WO2005034967A1 (en) * | 2003-10-10 | 2005-04-21 | Hans-Joachim Lach | Pharmaceutical or cosmetic compositions for treating skin |
| DE10347824B4 (en) * | 2003-10-10 | 2011-08-11 | Lach, Hans-Joachim, Dr., 79331 | Pharmaceutical or cosmetic composition for the treatment of the skin |
| DE102004013607A1 (en) * | 2004-03-18 | 2005-10-06 | Beiersdorf Ag | Lipid combination against ash-colored skin |
| EP1609460A1 (en) * | 2004-06-24 | 2005-12-28 | The Procter & Gamble Company | Skin care compositions comprising fatty material having a melting temperature range of 21-40 C |
| JP2008508215A (en) * | 2004-07-30 | 2008-03-21 | マイコス イタリアーナ ディ コミーニ ミロ アンド チ. エッセ.ア.エッセ | N-acylated derivatives of dicarboxylic acids in amino acid and plant protein hydrolysates and their use in cosmetics and medicine |
| DE102005008299B4 (en) | 2005-02-23 | 2025-07-10 | Bio-Gate Ag | Cosmetic and/or dermatological formulation, process for its preparation and use of the formulation |
| WO2006103056A3 (en) * | 2005-03-30 | 2006-11-23 | Gerhard Sauermann | Topical product containing betaine for preventing and treating nappy rash |
| DE102005051889A1 (en) * | 2005-10-29 | 2007-05-03 | Apotheker Walter Bouhon Gmbh | Cosmetic or dermatological preparation for protection against photoaging |
| DE102006045389A1 (en) * | 2006-09-26 | 2008-03-27 | Maxim Markenprodukte Gmbh & Co. Kg | Topically acting dermatological humectant comprises hyaluronic acid and panthenol in the multilamellar layers of hydrogenated liposomes |
| JP2013227353A (en) * | 2007-04-27 | 2013-11-07 | Fancl Corp | Milky lotion cosmetic |
| JP2008291014A (en) * | 2007-04-27 | 2008-12-04 | Fancl Corp | Milky liquid cosmetics |
| JP2010043027A (en) * | 2008-08-13 | 2010-02-25 | Kracie Home Products Ltd | Oil-in-water type emulsified cosmetic |
| DE102009008940A1 (en) | 2009-02-13 | 2010-08-19 | Rolf Ludl | Combination, useful for the cosmetic and/or medical treatment, and for producing a cosmetic product or a drug, comprises a hyaluronic acid gel and a cream in separate preparations |
| US20120122936A1 (en) * | 2010-11-11 | 2012-05-17 | Conopco, Inc., D/B/A Unilever | Leave-on nonsolid skin conditioning compositions containing 12-[(12-hydroxyoctadecanoyl)oxy] octadecanoic acid |
| EA026733B1 (en) * | 2011-05-12 | 2017-05-31 | Юнилевер Н.В. | Skin lightening composition |
| WO2012152568A3 (en) * | 2011-05-12 | 2013-09-26 | Unilever N.V. | A skin lightening composition |
| US9717666B2 (en) | 2011-05-12 | 2017-08-01 | Conopco, Inc. | Skin lightening composition |
| WO2013023641A2 (en) | 2011-08-16 | 2013-02-21 | Gabriele Blume | Method for producing a composition for application to the skin |
| DE102011110749A1 (en) | 2011-08-16 | 2013-02-21 | Gabriele Blume | Cosmetic or pharmaceutical composition with lamellar structures using sucrose fatty triesters - simple and easy preparation |
| DE102012023927A1 (en) * | 2012-12-06 | 2014-06-12 | Heinrich Huber | Ointment useful for treating psoriasis without side effects, comprises natural materials, extracts of salt pork, white beeswax and lavender oil, and does not contain preservatives |
| WO2017063748A1 (en) | 2015-10-16 | 2017-04-20 | Bernd Kuhs | Composition and method for producing dermatological and cosmetic preparations having pronounced lamellar structures using phosphatidycholine and fermentation by microorganisms |
| WO2018069814A1 (en) | 2016-10-11 | 2018-04-19 | MAUSER, Johannes, Alois | Method for producing dermatological and cosmetic preparations |
| KR20200022481A (en) * | 2017-06-30 | 2020-03-03 | 아테니온 아게 | Dissolving method of poorly soluble cosmetics |
| WO2019001770A1 (en) * | 2017-06-30 | 2019-01-03 | Athenion Ag | Method for solubilizing poorly water-soluble cosmetic agents |
| US11207256B2 (en) | 2017-06-30 | 2021-12-28 | Athenion Ag | Method for solubilizing poorly water-soluble cosmetic agents |
| KR102706051B1 (en) * | 2017-06-30 | 2024-09-12 | 아테니온 아게 | Dissolution method of insoluble cosmetics |
| EP3421096A1 (en) * | 2017-06-30 | 2019-01-02 | Athenion AG | Method for solubilizing poorly water-soluble cosmetic agents |
| WO2019086195A1 (en) | 2017-11-06 | 2019-05-09 | Cosmetolab Ag | Process for preparing topical formulations by means of ultrasound and formulations so obtained |
| CN111587243A (en) * | 2018-01-11 | 2020-08-25 | 麦翠奥制药公司 | Method for solubilizing 5-amino-2, 3-dihydro-1, 4-phthalazinedione |
| US20210061771A1 (en) * | 2018-01-11 | 2021-03-04 | Metriopharm Ag | Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione |
| CN111587243B (en) * | 2018-01-11 | 2024-04-12 | 麦翠奥制药公司 | Method for solubilising 5-amino-2, 3-dihydro-1, 4-phthalazinediones |
| US12122753B2 (en) * | 2018-01-11 | 2024-10-22 | Metriopharm Ag | Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19857492A1 (en) | Cosmetic or dermatological skin-protective compositions, containing saturated phosphatidyl choline to give good barrier stabilizing and active agent penetrating effects | |
| DE60209213T2 (en) | Translucent nanoemulsion, its method of preparation and its uses in cosmetics, dermatology and / or ophthalmology | |
| DE69900264T3 (en) | Nanoemulsion of ethoxylated fatty alcohol ethers or ethoxylated fatty acid esters and their uses in cosmetics, dermatology and / or ophthalmology | |
| DE69500013T2 (en) | Cleansing agent containing lipidic grains | |
| DE69400333T2 (en) | Cosmetic and dermatological compositions containing a combination of ceramides and linoleic acid | |
| DE60213449T2 (en) | COMPOSITIONS CONTAINING AN ETHANOLAMINE DERIVATIVE AND ORGANIC METAL SALTS | |
| DE3125710A1 (en) | "COSMETIC AGENTS" | |
| DE4021082C2 (en) | High lipid-containing skin treatment agent using a bilayer-containing system, organic acid salts, alcohol and stabilizer | |
| DE69912760T2 (en) | USE OF TOPICAL FORMULATIONS OF THE OIL-IN-WATER TYPE CONTAINING GALACTOLIPID MATERIAL AS AN EMULSION AGENT TO GIVE A LONG-LASTING EFFECT OF AN ACTIVE ACTIVE SUBSTANCE CONTAINING IT | |
| CH656307A5 (en) | PREPARATION FOR LOCAL ACNE TREATMENT. | |
| EP2029089B1 (en) | O/w emulsion for caring for hands | |
| DE19857491A1 (en) | Cosmetic or dermatological skin-protective compositions, containing UV filter and saturated phosphatidyl choline to give good barrier stabilizing and active agent penetrating effects | |
| DE102022108329A1 (en) | Composition for treating the skin | |
| DE19857489A1 (en) | Cosmetic or dermatological skin-protective compositions, containing triglycerides and saturated and unsaturated phosphatidyl choline to give good barrier stabilizing effects | |
| JP2025083496A (en) | Cosmetic compositions comprising sucrose esters and solvents | |
| KR101460777B1 (en) | Cosmetic composition for improving acne | |
| DE19857490A1 (en) | Cosmetic or dermatological skin-protective compositions, containing saturated and unsaturated phosphatidyl choline to give good barrier stabilizing and active agent penetrating effects | |
| DE102006045389A1 (en) | Topically acting dermatological humectant comprises hyaluronic acid and panthenol in the multilamellar layers of hydrogenated liposomes | |
| DE69500018T3 (en) | Oily scrub gel | |
| DE102005003708B4 (en) | Use of skin care oil with cocoa butter | |
| DE19735518C1 (en) | Rinsable emulsions for use as tallow-dissolving preparations | |
| EP2705828A1 (en) | Quick-penetrating, soft skin care cream | |
| EP3952822A1 (en) | Composition for a topical application on the skin | |
| JP7620104B2 (en) | Method for producing a cosmetic composition comprising a sucrose ester and a solvent | |
| DE102005008299B4 (en) | Cosmetic and/or dermatological formulation, process for its preparation and use of the formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8122 | Nonbinding interest in granting licences declared | ||
| R079 | Amendment of ipc main class |
Free format text: PREVIOUS MAIN CLASS: A61Q0017040000 Ipc: A61Q0017000000 |
|
| R079 | Amendment of ipc main class |
Free format text: PREVIOUS MAIN CLASS: A61K0007400000 Ipc: A61Q0017000000 Effective date: 20110719 Free format text: PREVIOUS MAIN CLASS: A61Q0017040000 Ipc: A61Q0017000000 Effective date: 20110719 |
|
| R082 | Change of representative |
Representative=s name: GILLE HRABAL, DE |
|
| R016 | Response to examination communication | ||
| R016 | Response to examination communication | ||
| R079 | Amendment of ipc main class |
Free format text: PREVIOUS MAIN CLASS: A61Q0017000000 Ipc: A61K0008550000 |
|
| R082 | Change of representative |
Representative=s name: GILLE HRABAL, DE |
|
| R079 | Amendment of ipc main class |
Free format text: PREVIOUS MAIN CLASS: A61Q0017000000 Ipc: A61K0008550000 Effective date: 20130320 |
|
| R081 | Change of applicant/patentee |
Owner name: LAUTENSCHLAEGER, HANS, DR., DE Free format text: FORMER OWNERS: LAUTENSCHLAEGER, HANS, DR., 50259 PULHEIM, DE; KUHS GMBH & CO, 79541 LOERRACH, DE Effective date: 20130416 Owner name: LAUTENSCHLAEGER, HANS, DR., DE Free format text: FORMER OWNER: HANS LAUTENSCHLAEGER, KUHS GMBH & CO, , DE Effective date: 20130416 |
|
| R082 | Change of representative |
Representative=s name: GILLE HRABAL, DE Effective date: 20121108 Representative=s name: GILLE HRABAL, DE Effective date: 20130416 |
|
| R084 | Declaration of willingness to licence |
Effective date: 20130605 |
|
| R120 | Application withdrawn or ip right abandoned |